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The  tumor  stroma  plays  an  important  role  in  tumorigenesis.  During  cancer 
progression  it  undergoes  changes  in  architecture,  gene  expression  and  secretion  of 
proteolytic  enzymes  that  are  essential  for  the  invasive  and  metastatic  phenotype  of 
malignant  tumors.  Cancer  associated  fibroblasts  (CAFs)  represent  the  major  cellular 
component of the stroma and recent studies demonstrated the prognostic and therapeutic 
significance of CAF‐related molecular signatures. 
The  identification  and  characterization  of  genes  and  signaling  pathways  involved  in  the 
molecular interactions between tumor and stromal cells has been the focus of this study. For 
that  purpose we  have  used  two  complementary  approaches:  the  identification  of  novel 
tumor  stroma  targets  in  human  colon  cancer  samples  using  whole  genome  Affymetrix 
GeneChip®  analysis  and  the  validation  of  theses  targets  in  a  newly  established  of  3D  co‐
culture model that mimics the cellular and molecular heterogeneity of human cancers. We 
have  demonstrated  increased  expression  of  gene  sets  related  to  hypoxia,  epithelial‐to‐
mesenchymal  transition  (EMT)  and  TGFβ  pathway  activation  in  CAFs  vs  their  normal 
counterparts  in both  systems. The putative TGFβ  target  IGFBP7  (insulin‐like growth  factor 
binding protein 7) was  identified as a  tumor  stroma marker of epithelial cancers and as a 
tumor antigen in mesenchyme‐derived sarcomas. IGFPB7 was shown to promote anchorage‐
independent growth  in malignant mesenchymal cells and malignant epithelial cells with an 











Das  Tumor‐Stroma  ist  für  das  Tumorwachstum  entscheidend.  Im  Zuge  der  Tumor‐
Progression  verändert  sich  das  Stroma  hinsichtlich  seiner  Zusammensetzung  sowie  seines 
Genexpressionsmusters und begünstigt durch die Freisetzung von proteolytischen Enzymen 
und  Wachtumsfaktoren  das  lokale  Tumorwachstum  und  die  metastatische  Ausbreitung. 
Tumor‐assoziierte  Fibroblasten  (TAFs)  bilden  die  zelluläre Hauptkomponente  des  Stromas 
und sind vorrangig für die Produktion dieser Faktoren verantwortlich. TAFs gewinnen daher 
als mögliche Angriffspunkte für gezielte Tumortherapien zunehmend an Bedeutung. Neuere 
Studien  unterstreichen  zudem  die  prognostische  Relevanz  TAF‐bezogener 
Genexpressionsmuster. 
Der Fokus dieser Studie  liegt auf der  Identifizierung und Charakterisierung von Genen und 
Signaltransduktionswegen, welche  in die molekularen  Interaktionen  zwischen  Tumor‐ und 
Stromazellen  involviert  sind. Zu diesem Zweck bedienten wir uns  zweier unterschiedlicher 
Ansätze: der  Identifizierung von neuen Tumor‐Stroma Markern  in Gewebeproben humaner 
Kolonkarzinome  durch  genomweite  Genexpressionsanalyse  mittels  Affymetrix  GeneChip® 
und  der  Validierung  der  so  identifizierten  Marker  in  einem  neu  etablierten 
dreidimensionalen  in  vitro  Co‐Kultur  Modell,  welches  die  zellluläre  und  molekulare 
Heterogenität humaner Tumore widerspiegelt. 
Im Vergleich  von  „normalen“  Fibroblasten und  TAFs,  zeigen  TAFs  in  beiden  Systemen  ein 
deutlich erhöhtes Expressionslevel von Genen, die mit Hypoxie, epithelialer‐mesenchymaler 
Transition  (EMT)  und  TGFβ‐Aktivierung  in  engem  Zusammenhang  stehen. Das  potentielle 
TGFβ‐Zielgen IGFBP7 wurde im Zuge dieser Analyse als Tumor‐Stroma Marker in epithelialen 
Tumoren  identifiziert, während  IGFBP7  in Tumoren mesenchymalen Ursprungs  (Sarkomen) 
als  Tumor‐Antigen  fungiert. Weiters  konnten wir  zeigen,  dass  IGFBP7  in mesenchymalen 











Solid  tumors  consist  of  a  complex mixture  of  neoplastic  epithelial  cells  and  non‐
neoplastic  cells,  collectively  referred  to  as  “tumor  stroma”.  These  include  specialized 




molecular  composition  of  the  tumor  stroma  correlates  with  prognostic  factors,  patient 
survival and response to treatment in several cancer types [2‐5].  
Tumor growth beyond a critical  size of 1‐2 mm3  is dependent upon  the  formation of new 
capillaries and the process of tumor‐induced angiogenesis (neoangiogenesis) has become  
 
Figure  1.  Histological  heterogeneity 




tumor  cells  (TC)  and  stromal  cells 
including  fibroblasts  (white 
arrowheads),  endothelial  cells 
forming  blood  and  lymphatic  vessels 
(BV, LV; area of presence marked with 
dashed red or blue lines, respectively) 
and  immune  cells  (black  arrows), 













[8,  9].  Tumor  blood  vessels  are morphological  and  functional  different  from  their  normal 
counterparts,  they  are  irregularly  shaped,  dilated,  tortuous  and  often  have  dead  ends. 
Furthermore, tumor blood vessels carry distinct molecular markers  in their endothelium,  in 




including  collagens  and  structural  proteoglycans,  as well  as  various  classes  of  proteolytic 
enzymes,  such  as  cysteine‐,  serine‐,  and  matrix  metalloproteases  (MMPs)  and  a  broad 
variety of growth factors [11]. Examples of growth factors that are highly expressed by CAFs 







[16],  α‐smooth muscle actin  (α‐SMA)[17], platelet‐derived growth  factor  (PDGF)  receptors 
[18] and fibroblast specific protein (FSP)‐1 [19]. This heterogeneity in marker expression may 
in part be explained by  the diverse origin of CAFs, which are  reported  to be derived  from 
resident  local  fibroblasts,  bone‐marrow  derived  progenitor  cells  or  from  transformed 




















endosialin  is  shown  which 
consists of an N‐terminal signal 
leader  peptide  (triangle),  a  C‐
type  lectin  domain  (C‐LEC),  a 
Sushi/SCR/CCP  domain  (S), 
three  EGF‐like  repeats  (EGF), 
the mucin domain (MUCIN), the 
transmembrane  domain  (TM) 
and  a  short,  cytoplasmic  tail 
(CYT). In human tumors endosialin is specifically expressed by tumor endothelial cells, pericytes and 
activated  tumor  fibroblasts, as demonstrated by  IHC on  this colon adenocarcinoma. The protein  is 
undetectable in normal tissues, as in the example of the normal colonic mucosa shown here [21]. 
 
leading  to  the  alternative  designation  of  tumor  endothelial  marker  1  (TEM1)[23]. 
Endosialin/TEM1  is expressed  to varying degrees by  tumor endothelial cells, pericytes and 




mouse  protein,  we  generated  a  mouse  specific  peptide  antibody  and  characterized  its 
specificity to bind to mouse endosialin by immunoblotting and by immunocytochemistry on 
mouse  endosialin  transfected  293T  cells.  Analysis  of  endosialin  expression  during mouse 
embryonic  development  by  immunohistochemistry  (IHC)  revealed  that  the  protein  was 
selectively expressed by the endothelial cells of the dorsal aorta in 9.5‐day embryos (Fig.3). 






The  endothelial  nature  of  the  stainings  was  confirmed  using  additional  endothelial  cell 















the  brain.  The  number 
and  pattern  of 
endosialin‐positive 





vascular  structures  in  the adult mouse as  shown here on a  section  from  the brain. The only adult 
tissue with  endosialin  expression was  the  uterus, with  endosialin  expression  seen  in  fibroblastic 
stromal  cells of  the  cycling  endometrium.  In  subcutaneous  cancer  xenograft models,  endosialin  is  




invagination  (e.g. optic  cup, oropharynx,  lung buds and hair  follicles).  In  the adult mouse, 
endosialin/TEM1  was  undetectable  in  blood  vessels  or  mesenchymal  cells  in  all  organs 
examined,  with  the  exception  of  the  uterus,  in  which  endosialin  was  present  in  the 
endometrial fibroblasts. Comparable to the expression patterns observed in human tumors, 
endosialin/TEM1, was found to be expressed by endothelial cells and fibroblasts in the tumor 




orthotopically onto  the  serosal  surface of  the  large  intestine of nude  endosialin  ‐/‐ mice, 




endosialin might  play  an  important  role  in  tumor  progression  [28].  Recent  studies  have 
shown that endosialin/TEM1 might interact with extracellular matrix components, including 
collagen type I, IV and fibronectin, suggesting that endosialin may be involved in promoting 
cell  adhesion  and  migration  processes  during  tumor  invasion  and  metastasis  [29].  A 
humanized Endosialin/TEM1 blocking antibody  (MORAb‐004)  is currently  in clinical studies 
and  based  on  its  ability  to  target  the  endothelial  cells  and  the  peri‐vascular  stromal 
component of the tumors it might provide a therapeutic benefit in a broad range of tumors. 
2.3  Fibroblast activation protein alpha (FAPα) 
Fibroblast  activation  protein  alpha  (FAP)  is  an  integral  cell  surface  protein 






Figure  4.  FAPα  structure  and  function. 
FAPα is a 95‐kDa type II transmembrane  
glycoprotein    and  belongs  to  the  post‐
proline  dipeptidyl  aminopeptidase 
family.  The  catalytic  domain  of  FAPα 
contains  a  serine  protease  consensus 
sequence in which the catalytic triad has 
been identified. FAPα has been shown to 
function  as  a  homodimer  and  is 
expressed  in  >90%  of  common  human 
epithelial  cancers  by  cancer  associated 
fibroblasts  as  demonstrated  here  in 
colon,  breast  and  pancreas  carcinomas. 
FAPα  is  not  detected  in  normal  adult 





FAPα activity  can be detected  in  tumor  samples and  shows a good  correlation with FAPα 
expression detected by IHC [32, 34]. Based on its selective expression in the reactive stroma 




recently  developed  a  novel  antibody‐maytansinoid  conjugate  (FAP5‐DM1),  targeting  a 
shared  epitope  of  human, mouse  and  cynomolgus monkey  FAP. Using  this  conjugate  in 
stroma‐rich  histotypic  cancer  xenograft  models  we  were  able  to  induce  long‐lasting 
inhibition of tumor growth and complete regressions  in models of  lung, pancreas and head 
and neck cancers, with no evidence of toxicity [36] (Fig.5). 
The  second  approach was  to  target  the  enzymatic  activity  of  FAP with  small molecule 




cancer  xenograft  models.  Nude  mice  bearing 
established LXFA629  lung  tumors were  treated 
i.v. with either vehicle control (PBS; green, filled 
square)  or mAb  FAP5‐DM1  at  400  µg/kg DM1 
(purple,  filled  square)  for  four  cycles.Tumor 
sizes are  represented as median of six or eight 
mice.  Arrows  indicate  days  of  treatment. 
Morphologic  changes  upon  treatment  are 












Transcriptional  profiling  of  cancer  specimens  has  provided  novel  insights  into  the 
molecular  characterization  of  tumors.  Expression  signatures  are  being  used  to  generate 
diagnostic  tools  and  prognosis  predictors  and  to  provide  new  genetic markers  that may 
serve  as  novel  therapeutic  targets  [38‐41]. Most  of  these  studies  have  used  bulk  tumor 
samples, therefore the specific contribution of malignant epithelial cells and stromal cells to 
the signatures  is unclear  in most cases. The method of  laser capture microdissection (LCM) 
to obtain selected populations of cells from tumors has provided considerable advantages to 
the  bulk methods  [2,  42].  However,  as  the  challenge was  to  distinguish  normal,  resting 
stromal  cells  from  reactive  stromal  changes  in  cancer  tissues,  LCM  guided  exclusively  by 
general tissue stains,  for  instance haematoxylin/eosin  (H&E) may not have been sufficient. 
For  this  purpose, we  have  implemented  existing  antibody  labeling  protocols  [43,  44]  and 
developed a novel protocol that reduced the critical staining time and enabled us to extract 
high quality RNA after  the  immuno‐LCM  (iLCM) procedure. Moreover, we used  the highly 







Figure 6.  Immuno‐LCM  (iLCM).  Laser  capture microdissection  (LCM)  is  a  technology  for  rapid  and 
easy  procurement  of  pure  cellular  subpopulations  from  its  complex  tissue  milieu,  under  direct 
microscopic visualization. To capture the selected cells, a thin polymer film is placed in direct contact 
with the section. A  laser beam then activates the polymer and transfers the cells onto the polymer 




In  order  to  identify  novel  tumor  stroma  targets  and  to  analyze  the molecular  pathways 
activated  in CAFs, we examined a set of colon cancer samples  including their normal tissue 
counterparts with  our  iLCM  screen  and  performed whole  genome  Affymetrix  GeneChip® 







Figure  7. Work  flow  for  identification  of  novel  tumour  stroma markers  by  expression  profiling 
analysis. The antibody‐guided laser capture microdissection allowed the separation of epithelial cells 
from  the  activated  stromal  compartment  in  colon  cancer  samples.  Activated  tumor  stromal 
fibroblasts were visualized by immunohistochemical staining with an antibody to FAPα . In the figure, 
the  borders  between  epithelial  and  stromal  structures  are  indicated  by  red  dotted  lines. Normal 
fibroblasts were  isolated  from normal  colonic  tissue after hematoxylin  staining and morphological 
examination. After RNA isolation and amplification whole genome Affymetrix GeneChip® analysis was 











fashion  by  Wnt‐1  released  by  the  tumor  cells  [46,  47]  and  to  bind  to  biglycan  on  the 







For  the  further  identification  of  tumor‐stroma  specific  genes  we  used  the  gene‐set 
enrichment  analysis  (GSEA)  with  two  gene‐set  collections  derived  from  the  Molecular 
Signature Database  (Broad  Institute):  the  curated‐gene  sets,  c2  and  the  c5  gene ontology 
(GO)‐gene  sets  [50].  Among  the  GO  datasets most  significantly  enriched were  gene  sets 
involved  in  wound  healing,  extracellular  matrix  deposition,  inflammatory  response,  cell 
migration,  cytokine  activity,  cell‐matrix  adhesion,  vascular  development,  collagens, 
transmembrane  receptor  tyrosine  kinase  activity,  cell‐cell  adhesion,  angiogenesis,  MMP 
activity, insulin receptor signaling and response to hypoxia (Fig.8). In addition, we identified 
192  significantly  enriched  curated  gene  sets  including  gene  sets  related  to  hypoxia, 
epithelial‐to‐mesenchymal transition (EMT), IL‐6 and TGFβ pathway activation.  
Enriched  hypoxia  related  gene  sets  contained  several  genes  encoding  angiogenic  growth 
factors  such  as  VEGFC  or  angiopoetin‐like  4  (ANGPTL4).  Other  genes  in  that  category 
encoded  collagens  (COL1A2, COL4A1, COL5A1, COL9A1 and COL18A1) and  their modifying 
enzymes  lysyl  oxidases  (LOXs)  and  lysyl  oxidase‐like  2  (LOXL2).  Recently,  collagen  cross‐
linking has been identified as a critical regulator of desmoplasia implying that the nature and 
level  of  ECM  cross‐links  could  impact  cancer  risk  and  alter  tumor  behavior  [51].  Lysyl 
oxidases are copper‐dependent amine oxidases  that  initiate  the process of covalent  intra‐ 
and  intermolecular cross‐linking of collagens  [52]. They are up‐regulated  in many  types of 
cancer [53] and are induced by hypoxia inducible factor (HIF‐1) and TGFβ, two key regulators 
of  tumor  growth  [54].  Interesting  examples  for  enriched  genes  related  to  IL‐6  treatment 
comprised  several pro‐inflammatory  cytokines  such as CXCL3 or  IL‐6  itself.  IL‐6  is  induced 
during wound healing,  is up‐regulated  in  fibroblasts during  fibrosis  and  is  associated with 
chronic  inflammatory disease such as rheumatoid arthritis  [55]. Gene‐sets  involved  in EMT 













Figure  8.  Genes  and  gene‐sets  induced  in  the  tumor  stroma. Well  characterized  tumor  stroma 
markers  such  as  FAPα  ,  biglycan  or Wisp‐1 were  found  to  be  significantly  elevated  in  the  tumor 
stroma  compartment  vs.  the  normal  stroma.  The  expression  levels  are  indicated  by whisker  box 
plots,  the bold  centre‐line  indicates  the median;  the box  represents  the  interquartile  range  (IQR). 
Whiskers  extend  to  1.5  times  the  IQR.  TC,  tumor  cells;  NS,  normal  stroma;  TS,  tumor  stroma. 






























































vessels  and  activated  tumor  fibroblasts  in  colorectal  cancer  samples.  Further  stainings  of 
different  tumor  types  revealed  that  IGFBP7  is  frequently  induced  in  the  stromal 
compartment of epithelial cancers and that in soft tissue sarcomas, IGFBP7, is expressed by 
the malignant mesenchymal  cells.  (Fig.9).  The  expression  in malignant mesenchymal  cells 
was also confirmed by Western blotting on a panel of cell  lines,  including the fibrosarcoma 
line HT1080. Moreover, high expression of  IGFBP7 was observed  in cancer cell  lines which 
have  undergone  EMT  ,  such  as Caki‐1  and  SW480, whereas  colon  cancer  cell  lines which 
maintained an epithelial phenotype such as LS174T, HT‐29, DLD‐1 lacked IGFBP7 expression. 
To establish  the potential  role of  IGFBP7,  shRNA mediated knock‐down experiments were 
carried  out  in  HT1080  and  Caki‐1  cells.  The  knock‐down  resulted  in  >90%  reduction  of 
IGFBP7 on the protein level and in a significant reduction in the number of colonies growing 
anchorage independently in soft‐agar culture, indicating that in those cells IGFBP7 acts as a 
promoter  of  anchorage‐independent  growth  (Fig.10). On  the  other  hand, we  could  show 
that  IGFBP7  reduces  anchorage‐independent  growth  when  overexpressed  in  tumor  cells 
with an epithelial phenotype such as  in  the colon cancer cell  line DLD‐1 and  that  in  those 
cells,  IGFBP7  is present as a  two‐chain  form, which previously has been reported  to result 
from  proteolytic  cleavage  by  the  type  II  transmembrane  serine  protease matriptase  [64]. 
Matriptase  is a strictly epithelial serine protease and processing of  IGFBP7 by  this enzyme 






Figure  10. IGFBP7  is  expressed  by malignant mesenchyme‐derived  cells  and  tumor  cells with  a 
mesenchymal  phenotype  and  promotes  anchorage‐independent  growth  in  these  cells.  As 
demonstrated by Western blotting, IGFBP7 is expressed by fibrosarcoma cells HT1080 and epithelial 




In  HT1080  cells,  shRNA mediated  IGFBP7  knock‐down  resulted  in  >90%  protein  reduction  in  the 





acquired  a  mesenchymal  phenotype  after  undergoing  EMT.  To  further  substantiate  this 
model, we have knocked‐down E‐cadherin in DLD‐1 cells. These knock‐down cells displayed a 
mesenchymal  phenotype,  activation  of  β‐catenin  and  a  significant  induction  of  IGFBP7 






In summary, we have shown  that cancer‐associated  fibroblasts express  increased  levels of 
genes  related  to  EMT  and  TGFβ‐induction  and  that  IGFBP7,  a  tumor  stroma marker  and 
potential TGFβ  target might have a dual  function as a  tumor  suppressor of  tumor growth 
during early tumorigenesis or as a promoter of tumor growth in later stages . 
2.6  3D in vitro model system to study tumor ‐ tumor stroma interactions 
In  order  to  study  the molecular mechanism  that  control  the  heterotypic  tumor  ‐ 
tumor stroma interactions in vitro, we have developed a novel 3D in vitro co‐culture system, 
which recapitulates the tumor heterogeneity observed  in vivo  (Dolznig H et al., submitted) 
(Fig.11).  Cells  grown  in  three‐dimensional  (3D)  scaffolds  or  as  3D multicellular  spheroids 
more closely resemble the architecture of tissues and tumors  in vivo than conventional 2D 
cultures. Moreover,  they offer  the opportunity  to analyze  the activation of differentiation 
programs and the pathways involved in cell migration and invasion as the tumor cells in this 
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The tumor stroma plays an important role in tumorigenesis. During cancer progression 
the tumor stroma undergoes changes in architecture, gene expression, secretion of soluble 
factors and extracellular matrix deposition that are essential for the malignant epithelial cells 
to manifest the invasive and metastatic phenotype of malignant tumors. Altered gene 
expression in these non-transformed stromal cells has provided potential targets for therapy. 
Assessing the therapeutic utility of this new class of drugs requires the use of in vitro and in 
vivo tumor models that recapitulate the complex molecular and structural interactions between 
the malignant cells and the surrounding stroma. Appropriate in vivo models are also needed 
that are suitable to determine the efficacy and tolerability of the drugs. Considerable advances 
have been made in this respect and a number of drugs targeting signaling pathways of 
activated tumor fibroblasts are in clinical development. 





The tumor stroma is an essential, intrinsic part of epithelial cancers and plays a 
primary role during carcinogenesis. Extensive clinical evidence and a variety of experimental 
mouse models have demonstrated the active role of the tumor stroma in promoting tumor 
growth. The advances in our understanding of the molecular basis for cancer initiation and 
progression provide the basis for the design of novel targeted agents that selectively address 
deregulated pathways in malignant cells. Drugs that target the stromal component of tumors 
may represent a further important approach to the overall control of cancer. 
The discovery and development of molecularly targeted drugs requires translational research, 
which include the identification of new molecular targets, target validation and the 
development of appropriate models to test the new drugs with regard to their mechanism of 
action, safety and efficacy before translating these findings into the clinic. 
Here we will address the challenges for drug development of new therapeutic agents directed 
towards the tumor stroma, in particular those targeting the cancer associated fibroblasts 
(CAFs), the limitations in the available experimental models and the complexity of the model 
systems in which the new targets can be studied in detail.  
Histological and molecular heterogeneity of human cancers 
Carcinomas which comprise the majority of human cancers are composed of 
malignant epithelial cells as well as mesenchyme-derived stromal cells, such as fibroblasts, 
myofibroblasts, endothelial cells, pericytes, smooth muscle and hematopoietic cells embedded 
in a matrix of extracellular proteins (ECM). Different histological subtypes of carcinomas 
exist and the extent and composition of the stroma differs among tumors. Certain tumor types 
such as those occurring in the pancreas, breast, and colon (Fig. 1) are characterized by the 
presence of a prominent stromal reaction (desmoplasia). The fibroblasts in those tumors 
express markers of activated fibroblasts such as fibroblast activation protein alpha (FAPα) [1] 
and alpha-smooth muscle actin (α-SMA) [2] that differ from their expression in resting 
fibroblasts of the adjacent normal tissues (Fig. 1A), indicating the phenotypic differences 
between normal and tumor fibroblasts. Different subsets of CAFs have been observed to 
occur in different tumor types [3,4] suggesting that the activation programs of CAFs in cancer 
may be linked to the tissue of origin and might indicate functional differences of CAFs in 
tumor invasion and metastasis [5]. Several clinicopathologic studies have shown that the 





Cancer associated fibroblasts (CAFs): Molecular characterization 
Fibroblasts represent the major cellular component of the stroma of epithelial cancers. 
Several in vitro and in vivo studies have demonstrated that the growth, differentiation and 
invasive behaviour of malignant epithelial cells are influenced by the surrounding stroma [8-
11]. Normal fibroblasts have been reported to prevent the progression of transformed 
epithelial cells [12], in contrast, the presence of activated tumor stromal fibroblasts was 
shown to enhance malignant epithelial transformation in several cancer models [13-15]. 
Cancer associated fibroblasts (CAFs) differ considerably from normal resting fibroblasts, and 
display distinct molecular signatures which can be linked to clinical outcome [16]. Recent 
studies have identified new functional roles for CAFs and the existence of different CAFs 
subsets in human cancers by gene expression analysis [17,18]. 
In vitro and in vivo models for tumor stroma interaction 
Understanding the molecular mechanisms that control the heterotypic interactions 
between malignant cells and the surrounding stroma may help to develop new targeted 
therapies. However these studies have been hampered by the challenges in studying multi-
cellular interactions in experimental models (Fig. 2). 
The in vitro study of freshly dissociated cancer cells or established tumor cell lines and 
fibroblasts in two dimensional (2D) cultures has provided important insights into basic tumor 
cell biology and has enabled the identification of common genetic alterations in cancer cells 
that can be targeted therapeutically [19-22] . However, such in vitro approaches have proven 
somewhat limited in studying stromal targets. Only a limited number of stromal-derived cells 
are available in culture and phenotypic changes can be induced under culture conditions [15]. 
In addition, many physiological aspects of tumors such as cell-cell and cell-matrix 
interactions are lost under conventional 2D culture conditions. 
Cells grown in three-dimensional (3D) scaffolds or as 3D multicellular spheroids recapitulate 
the architecture of tissues and tumors in vivo to a higher extent. They offer new opportunities 
to analyze the activation of differentiation programs and the pathways involved in cell 
migration and invasion when cells are grown in a heterotypic and physiologically relevant 
context [7,23]. Organotypic 3D co-culture models have been used to study the functional 
interplay between genetically altered epithelial cells and fibroblasts [24,25] and to study 
fibroblast-led invasion in models of skin, breast, pancreatic and brain cancers [26,27]. 
A novel experimental set-up has been developed (Dolznig H et al. manuscript in preparation) 




epithelial cancer cells with normal human fibroblasts or CAFs in one assay (Fig. 2). Using 
this model system the feasibility to study the tumor - stroma interactions phenotypically and 
at the molecular level was demonstrated. Gene expression profiles from these 3D co-cultures 
have been obtained and ongoing studies are exploring the applicability of the model to study 
the role of these new stromal targets in tumor invasion using knock-in/knock-down 
experiments of selected genes in the tumor cells or in the fibroblast population. 
Xenograft tumor models are commonly used to analyze new mechanisms of action and to 
validate the efficacy of novel drugs in preclinical studies. The majority of these in vivo assays 
are performed in immunodeficient mice following the inoculation of established tissue culture 
cell lines into ectopic sites. From a histopathological view these tumor models show a highly 
atypical morphology with very little stroma or histotypic features resembling the human 
cancer counterparts (Fig. 1B). A more authentic histological appearance is observed in 
carcinoma models derived by direct transplantation of surgical specimens, purified cell 
suspensions freshly obtained from surgical specimens or in orthotopically implanted tumors 
[28-31]. Nevertheless, most of the preclinical validation studies are carried out using the 
ectopic (mostly subcutaneous) in vivo models, that are relatively easy to set up and that can be 
generated in large numbers of similar-sized tumors for randomization as pre-requisite to 
assess the effects of drugs. However, in many cases, the results obtained from xenograft 
models do not translate well in subsequent clinical studies [31]. 
Genetically engineered mouse models (GEM) are promising alternatives [32,33]. These 
models, generated through the introduction of genetic mutations associated with specific 
human malignancies closely recapitulate the human disease at the pathophysiological and 
molecular level. To date, models have been developed for many common tumor types (e.g. 
lung, breast, prostate, colon and pancreatic cancer). Evidence for the usefulness of GEM has 
been demonstrated in preclinical studies evaluating targeted therapies in models of lung and 
breast cancer [9, 34-38]. These studies suggest that GEM can more accurately predict the 




Therapeutic opportunities  
Different molecular targets have been shown to distinguish the cancer associated 
fibroblasts (CAFs) and different strategies to target these molecules are under evaluation  
Here we will focus on potential drug candidates with special attention to those in more 
advanced clinical development.  
Fibroblast activation protein alpha  
Fibroblast activation protein alpha (FAP) is an integral cell surface protein 
selectively expressed by activated stromal fibroblasts of several types of human epithelial 
cancers. In normal tissues, FAP expression is highly restricted to developing organs, healing 
wounds, and tissue remodeling. Epithelial tumor cells and most normal adult human tissues 
lack FAP expression [1, 39-43]. FAP is a serine protease capable of degrading type I 
collagen which places FAPα into the group of enzymes involved in tumor tissue remodeling 
[44-46]. FAPα activity can be detected in tumor samples and shows a good correlation with 
FAPα expression detected by immunohistochemistry [42,45]. Based on the selective 
expression of FAP in the reactive stroma of many epithelial cancers, the lack of expression 
in normal adult tissues, and its protease activity, FAP is an ideally suited stroma target to be 
exploited in the clinic.  
Two different approaches have been used to target FAP in tumors. The first was to employ 
FAP -specific monoclonal antibodies. Initial studies with radiolabeled murine and 
humanized antibodies against human FAP have shown highly specific tumor targeting 
properties [47,48], however no clinical efficacy could be demonstrated using the unlabeled 
humanized antibody in a study in metastatic colorectal cancer [49], probably due to the lack 
of effector-function properties of the naked antibody. More recently, a novel antibody-
maytansinoid conjugate (FAP5-DM1), targeting a shared epitope of human, mouse and 
cynomolgus monkey fibroblast activation protein alpha, has been developed. Using this 
conjugate in stroma-rich histotypic cancer xenograft models we were able to induce long-
lasting inhibition of tumor growth and complete regressions in models of lung, pancreas and 
head and neck cancers, with no evidence of toxicity [31].   
The second approach has been to target the enzymatic activity of FAP with small molecule 
inhibitors. Using the peptidase inhibitor PT-100 (talabostat) a reduction in tumor growth rate 
was shown in a variety of tumor models in mice [50,51]. This particular compound, however, 




DPP7), so that the anti-tumor effect could not be directly attributed to FAP inhibition. More 
recently, using FAP-null mice and a more selective  inhibitor  (PT-630), the endogenous role 
of FAP in tumorigenesis and the control of tumor growth mediated by pharmacologic 
inhibition of FAPα enzymatic activity has been reported [38,52]. Deletion of FAP resulted 
in a marked reduction of tumor growth in a LSL-K-rasG12D genetic mouse model of lung 
cancer and in a syngeneic colon cancer model, suggesting a tumor promoting activity of 
endogenous FAPα. Treatment with PT-630 of tumor-bearing wild type animals resulted in a 
marked inhibition of tumor growth in both models, supporting further clinical studies.  
Matrix metalloproteinases (MMPs) 
Cancer associated fibroblasts are a major source of MMPs in tumors, including MMPs 
1,2,3,9,11,13 and MT1-MMP [53,54]. Fibroblast derived MMPs have been extensively 
investigated in xenograft models, demonstrating the important role for these proteases in 
promoting tumor growth, metastasis, and angiogenesis [55]. Based on the results of the 
preclinical studies MMPs were seen as attractive anticancer targets and several inhibitors have 
been developed and tested in the clinic in a variety of cancer types [56]. These trials however 
had failed to demonstrate a survival benefit despite the promising activity shown in pre-
clinical models [57]. Possible explanations include differences in the biology of the MMPs 
between mice and humans, lack of anti-immune response in the xenograft models used pre-
clinically, dose-limiting toxicities at least in part due to off-target effects, a narrow therapeutic 
window for some of the inhibitors and perhaps the challenging fact that MMPs can have 
tumor-promoting as well as tumor-suppressor activities. Thus a better understanding of the 
functional complexity of this family of proteases and the use of second generation inhibitors 
with improved selectivity profile  may provide better therapeutic outcomes [58]. 
Endosialin/TEM1 
Endosialin is a highly sialylated, C-type lectin-like surface receptor structurally related 
to thrombomodulin and complement receptor C1qRp [59,60]. First identified with a 
monoclonal antibody, mAb FB5, endosialin was discovered independently through a SAGE 
screen (serial analysis of gene expression) of human cancer endothelial cells, leading to the 
alternative designation of tumor endothelial marker 1 (TEM1) [61]. Endosialin/TEM1 is 
expressed to varying degrees by tumor endothelial cells, pericytes and stromal fibroblasts [62-
64]. Endosialin expression has not been detected  in capillary endothelium in most normal 
tissues. The physiological role of endosialin is unknown. Endosialin/Tem1 knock-out mice 




implanted orthotopically onto the serosal surface of the large intestine of nude KO mice, both 
tumor take and growth rate were reduced [65].  Recent evidence suggests that 
endosialin/TEM1 might interact with extracellular matrix components, including collagen 
type I, IV and fibronectin in promoting cell adhesion and migration processes during tumor 
invasion and metastasis [66].  A humanized Endosialin/TEM1 blocking antibody (MORAb-
004) is currently in clinical studies and might provide a therapeutic benefit in a broad range of 
tumors, based on its ability to target the endothelial cells as well as the peri-vascular stromal 
component of the tumors. 
PDGF/PDGFR pathway  
Platelet-derived growth factors (PDGFs) play important roles during embryonic 
development and wound healing [67] and expression of their tyrosine kinase receptors 
(PDGFRs) in the tumor stroma is a common feature of human cancers [68]. During 
tumorigenesis, PDGFR can drive tumor growth directly by autocrine stimulation of receptor-
expressing tumor cells or in a paracrine manner by acting on the tumor stroma fibroblasts and 
pericytes [69]. The importance of the paracrine signaling network for the recruitment of 
cancer associated fibroblasts and pericytes has been shown in a number of studies [70,71]. 
Pericytes provide both survival signals and structural support to endothelial cells contributing 
to a mature, functional vasculature and thus to tumor growth [72].  
Multiple tyrosine kinase inhibitors with anti-PDGFR activity, such as imatinib, sorafenib, and 
sunitinib, have been approved and are presently under further clinical development [73,74]. 
The most commonly used, imatinib, is  a bcr-abl inhibitor with additional PDGFR and c-kit 
kinase inhibitory activity [75]. In experimental cancer models, imatinib has been shown to 
inhibit PDGFR activity on fibroblasts and pericytes and to significantly decrease the stromal 
reaction which was accompanied by a reduction in tumor cell proliferation and pericyte 
coverage of tumor vessels [69,76].  Furthermore, inhibition of PDGFRs increases the uptake 
and therefore the antitumor effect of conventional chemotherapeutics like paclitaxel by 
lowering tumor interstitial pressure [77]. Other multi-kinase inhibitors, such as BIBF1120, a 
triple angiokinase inhibitor of the VEGFR, PDGFR and FGFR families, has been shown to 
decrease the pericyte coverage of tumor blood vessels in experimental cancer models [78] 
which together with the reduction in tumor microvessel density contributed to the pronounced 





Collectively, these results indicate that inhibition of PDGF receptor signaling might provide a 
complementary approach to conventional treatments. To date, it is still unknown to what 
extent selective blockage of stromal PDGF signaling contributes to the observed anti-tumor 
effects of these multi-kinase inhibitors. 
Transforming growth factor β (TGF-β) pathway 
Transforming growth factor β (TFG-β) is recognized for its dual and opposing 
functions, a tumor-suppressor activity in the pre-malignant state and a tumor promoter activity 
during malignant progression [79, 80]. This dual role has made the design and development of 
drugs targeting this signaling pathway in cancer particularly complex. In tumors, activation of 
TGF-β is linked to the activity of several oncogenic pathways linked to the induction of 
epithelial mesenchymal transition (EMT) that enhances tumor cell invasion [81]. TGF-β can 
have an additional role in tumor growth that is mediated through its activity on the tumor 
stroma, facilitating tumor tissue remodeling and neoangiogenesis. Studies with fibroblast 
specific TGF-β type II receptor knock-out models provided evidence for the tumor suppressor 
role of TGF-β in fibroblasts, by blocking the production of tumor cell growth-promoting 
paracrine factors such as HGF (hepatocyte growth factor) [9,82]. On the other hand, it was 
demonstrated that TGF-β stimulates myofibroblast differentiation and that blocking of TGF-β 
signaling in stromal fibroblast leads to a significant reduction of tumor-growth in a co-
transplantation xenograft model [83], suggesting that pro- or anti-tumoral effects of TGF-β 
signaling may very much depend on individual tumor models. Considering the direct effect of 
TGF-β on tumor cells and its indirect effect on the tumor stroma, TGF-β signaling appeared 
as an attractive therapeutic concept. Several approaches to inhibit the TGF-β pathway have 
been investigated in preclinical models and clinical studies. Neutralizing antibodies that 
inhibit the ligand-receptor interaction, antisense oligonucleotides and small molecule 
inhibitors of the TGF-β receptor kinase complex have been developed and are at different 
stages of clinical development [84,85]. It is expected that this class of agents will be active in 
a broad range of tumors but due to the complex roles of this growth factor receptor family in 
tumorigenesis a careful selection of patients will be required to address their therapeutic 
benefits in patients 
Hedgehog pathway 
The Hedgehog (Hh) family of proteins have been shown to control cell growth, 
survival and fate during embryonic development and when mutated or misregulated to 




associated with basal cell carcinoma of the skin, medulloblastoma and rhabdomyosarcoma 
[86] . Furthermore, components of the Hh pathway have been described to play a role in the 
growth of a variety of epithelial cancer types, including small cell lung cancer, pancreatic and 
prostate cancer even in the absence of mutations [87-89]. Recent studies in experimental 
cancer models support a model in which Hh acts in a paracrine manner on stromal cells. Hh 
increases tumor growth by stimulating the expression of extracellular matrix proteins and 
factors like IGF or Wnt in the stroma and thereby promoting stromal desmoplasia [90]. The 
most commonly used Hh antagonists are the plant alkaloid cyclopamine and its derivatives 
[91]. The anti-tumor effect of the semisynthetic cyclopamine-derivative IPI-926 was 
investigated in a mouse model of pancreatic ductal adenocarcinoma refractory to gemcitabine 
(a drug commonly used in the clinic). Mice treated with IPI-926 alone or in combination with 
gemcitabine were depleted of desmoplastic stroma reaction in the tumors and displayed 
increased intratumoral vascular density. These changes correlated with a more effective 
delivery of the co-administrated gemcitabine, resulting in enhanced efficacy of the drug [92]. 
This study has identified a potential novel mechanism for anti-stroma therapy. 
Identification of novel therapeutic targets by gene expression profiling  
The recent technological advances for high-throughput DNA and RNA detection have 
shown that specific germline and somatic mutations, loss of heterozygosity, and DNA 
amplifications occur during cancer progression. Oncogenome signatures of human tumors 
have been shown to correlate with metastatic behaviour and clinical outcome in different 
cancer types [93-95]. However, the specific contribution of malignant epithelial cells and 
stromal cells to these genetic signatures is in most cases unclear, since most of the studies 
have used bulk tumor samples. Our approach to establish the molecular differences between 
CAFs and normal resting fibroblasts has been to generate gene expression signatures from 
microdissected cancer and corresponding normal tissues. We focussed on colorectal cancer 
and developed a protocol for laser capture microdissection guided by antibodies against FAP 
to separate epithelial cells from activated stromal fibroblasts [96]. We performed whole 
genome Affymetrix GeneChip® analysis and obtained transcriptional signatures from tumor 
cells and activated tumor stroma that were compared with the expression profiles from 
microdissected normal colonic epithelium and normal fibroblasts, obtained from the same 
patients (Fig. 3, Rupp et al manuscript in preparation). Bioinformatic analysis comparing the 
tumor stroma vs. the normal stroma signatures identified a number of selectively up-regulated 




FGFR1 among others appeared specifically up-regulated in the stroma compartment (Fig. 3) 
and served as a validation parameter for our screen. To further analyze the functional 
significance of these gene signatures in the context of tumorigenesis we performed a similar 
genetic screen in our above described 3D co-culture model of tumor cell spheroids and 
fibroblasts (normal and cancer-derived) grown in collagen gels. We established transcriptional 
profiles from the different cellular components grown in collagen gels in mono-cultures and 
compared the gene expression responses induced upon co-cultivation (Dolznig et al. 
manuscript in preparation). We observed a remarkable concordance between the gene sets 
obtained in our ex vivo study (colorectal cancer study from human samples) and this in vitro 
co-culture system. Examples of commonly regulated genes included COL11A1 and MMP3 
(Fig. 3), well characterized markers of activated fibroblasts. Gene-Set Enrichment Analysis 
(GSEA) [97] using the gene-set collections from the Molecular Signature Database (Broad 
Institute) [98] and Pathway analysis (Ingenuity®) revealed datasets and gene-networks that 
were significantly enriched in both screens. Gene-sets involved in extracellular matrix 
deposition, angiogenesis, wound healing and EMT were significantly up-regulated in both 
studies.  
Interestingly, many of the genes identified in our study have been reported in studies 
performed in vitro including the “wound response signature” of fibroblasts in response to 
serum stimulation [99], a hypoxia-associated response [100] as well as the signatures obtained 
from co-cultures of cancer cells and fibroblasts cell lines of different origins [101,102]. Using 
independent datasets from human cancers, it was shown that the “wound-response signature” 
was strongly predictive of metastasis and progression in breast, lung and gastric cancers and 
was an independent predictor of outcome in a follow-up study in breast cancer [99]. 
Other in vivo signatures have been described [103]  comparing the expression patterns of 
good versus poor outcome in fibroblastic tumors. A subsequent comparison of these 
signatures with a breast cancer data set suggested that distinct patterns of stroma reaction 
defined two groups of breast cancers with significant differences in overall survival,indicating  
that the stromal response varies significantly in different subtypes of carcinomas and may be 
clinically relevant. Expression signatures from different tumor compartments have also been 
established using serial analysis of gene expression on antibody-sorted stromal components in 
breast cancers [104] or laser capture microdissection in breast cancer and basal cell carcinoma 
of the skin [105,106]. Using a set of genes expressed by the microdissected tumor stroma, a 
stroma-derived prognostic predictor signature (SDPP) was developed and shown to separate 




[16]. In another study, a stromal signature was shown to predict the response of estrogen-
receptor negative breast tumors to chemotherapy [107]. The authors used a novel 
bioinformatics method that decomposes gene expression signals from a mixture of tumor and 
stromal cells into multiple independent signatures. They obtained a 50-gene stromal signature 
including FAPα, MMP2, MMP14, PDGFR-β which predicted resistance to chemotherapy. 
Taken together, these studies demonstrated that tumors expressed a variety of functionally 
different genes in their tumor stroma, representing different activation stages or different 
subtypes of CAFs that may be relevant for the invasiveness or clinical behavior of the tumors. 
The gene expression signatures derived from this type of analysis appear to have clinical 
significance in different cancer types and have provided new genetic markers in the tumor 
stroma that may serve as targets for novel therapeutic approaches.  
Conclusions 
The rapid progress of research in molecular cancer biology has contributed to a better 
understanding of the role of the tumor stroma during tumor growth and metastasis formation 
and has led to the identification of selected tumor stroma markers that serve as targets for 
novel therapies. A number of monoclonal antibodies, small-molecule inhibitors and anti-sense 
approaches have been developed and investigated in pre-clinical models, some of these 
molecules have entered clinical development. Future approaches to stroma-targeted therapy 
will have to be based on further refinement of our understanding of the molecular 
mechanisms that control the tumor-stroma interaction, improved preclinical models that 
adequately reproduce the complexity of the tumor tissue, and a biomarker-based selection of 
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Figure legends  
Figure 1 
A. Cancer associated fibroblasts are the main cellular stromal component of carcinomas and 
display molecular heterogeneity. 
Carcinomas arising in the pancreas, breast and colon display prominent stroma reaction 
(desmoplasia) separating the clusters of tumor cells. The fibroblasts in those tumors express 
markers of activated fibroblasts such as fibroblast activation protein (FAPα) and alpha-
smooth muscle actin (α-SMA). FAPα is selectively expressed in the tumour stroma and is 
absent in normal tissues (see normal colon vs. colon cancer). In contrast, expression of α-
SMA can be seen in subsets of fibroblasts surrounding the crypts and in the muscularis 
mucosa of the normal colon as well as in activated tumor fibroblasts. FAPα and α-SMA 
expression (brown) visualized by the ABC immunoperoxidase method with hematoxylin 
counterstaining.  
B. Subcutaneous xenograft models in immunodeficient mice.  
Like in the majority of xenograft models, subcutaneous injection of Colo205 cells, a human 
colorectal cancer cell line, induces tumors with a highly atypical morphology, characterized 
by clusters of tumor cells, with very little tumor stroma, and absence of glandular 
differentiation (for comparison see the human colon cancer sample above). Certain human 
tumor cells such as FaDu cells, derived from a head and neck squamous cell carcinoma, are 
able to induce a more prominent stroma reaction, with FAPα positive activated stromal 
fibroblasts and histotypic features resembling the human counterpart. Therefore, a careful 
selection of the in vivo models is required to determine the efficacy of drugs targeting the 
activated tumor fibroblasts. Hemaoxylin-eosin and immunohistochemical staining for FAPα 
(brown; bottom panel). 
Figure 2 
Carcinomas are heterogeneous mixtures of malignant cells and stromal cells, such as 
fibroblasts, blood vessels and immune cells embedded in a matrix of extracellular proteins 
(ECM) and grow as three dimensional structures. An example for this heterogeneity is shown 
in a histologic picture from a human non-small cell lung cancer (left panel). Tumor cell 
clusters (blue) are separated by strands of activated fibroblasts which are PDGFR-β positive 
(brown) and blood vessels with CD31 positive endothelial cells (dark blue). In conventional 




culture conditions many features of the in vivo growth, such as tissue architecture, cell-cell 
contact, heterotypic cellular interactions and signaling networks are lost (middle panel). Using 
3D cultures in the presence of ECM components, the heterotypic interactions of tumor cells 
and stromal cells can be studied in detail. A phase contrast picture of this model shows a 
culture of tumor cells grown as a multicellular spheroid, co-cultured with fibroblast embedded 
in a collagen I gel, recapitulating the in vivo heterogeneity.  
Figure 3 
Identification of novel tumour stroma markers by expression profiling analysis.  
A. Antibody-guided laser capture microdissection allows the separation of epithelial cells 
from the activated stromal compartment in colon cancer samples. Activated tumor stromal 
fibroblasts were visualized by immunohistochemical staining with an antibody to FAPα . In 
the figure, the borders between epithelial and stromal structures are indicated by red dotted 
lines. Normal fibroblasts were isolated from normal colonic tissue after hematoxylin staining 
and morphological examination. After RNA isolation, whole genome Affymetrix GeneChip 
analysis was performed. Bioinformatic evaluation identified novel tumor stroma targets by 
comparing the tumor stroma vs. the normal stroma signatures.  
B. Well characterized tumor stroma markers such as FAPα , MMP2, PDGFRß and FGFR1 
were significantly up-regulated in the tumor stroma compartment. The expression levels are 
indicated by whisker box plots, the bold centre-line indicates the median; the box represents 
the interquartile range (IQR). Whiskers extend to 1.5 times the IQR. TC, tumor cells; NS, 
normal stroma; TS, tumor stroma. 
C. Comparison of the transcriptional profiles obtained in our ex vivo screen in colorectal 
cancer samples with those obtained in an in vitro screen with a colon cancer cell line 
(LS174T) cultured in the presence colon-derived human CAFs in a 3D co-culture assay. 
Gene-Set Enrichment Analysis (GSEA) revealed gene sets involved in extracellular matrix 
deposition, angiogenesis and wound healing significantly upregulated in both studies.Two 
representative examples, Collagen IX a1 (COL11A1) and matrix metalloprotease 3 (MMP3) 
are shown. TC, tumor cells; NS, normal stroma; TS, tumor stroma; blue whisker box blots 
indicate the expression levels after 3.5 days of LS174T/CAF co-cultivation (TC/CoCult); 
yellow box blots show the levels of expression of individually cultured LS174T cells and 
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The activated tumor stroma participates in many processes that control tumorigenesis, 
including tumor cell growth, invasion and metastasis. Cancer associated fibroblasts (CAFs) 
represent the major cellular component of the stroma and are the main source for connective 
tissue components of the extracellular matrix (ECM) and various classes of proteolytic 
enzymes. The signaling pathways involved in the interactions between tumor and stromal 
cells and the molecular characteristics that distinguish normal “resting” fibroblasts from 
cancer associated or “activated” fibroblasts remain poorly defined. Recent studies emphasized 
the prognostic and therapeutic significance of CAF-related molecular signatures and the 
identification of novel stromal targets.  
We have used immuno-laser capture microdissection and whole genome Affymetrix 
GeneChip® analysis to obtain transcriptional signatures from the activated tumor stroma of 
colon carcinomas that were compared with the expression profiles from normal resting 
fibroblasts. Several members of the Wnt-signaling pathway and gene sets related to hypoxia, 
epithelial-to-mesenchymal transition (EMT) and TGFβ pathway activation were induced in 
CAFs. The putative TGFβ target IGFBP7 was identified as a tumor stroma marker of 
epithelial cancers and as a tumor antigen in mesenchyme-derived sarcomas. IGFPB7 was 
shown to promote anchorage-independent growth in malignant mesenchymal cells and 
malignant epithelial cells with an EMT-phenotype, whereas a tumor suppressor function was 






Carcinomas consist of complex mixtures of neoplastic epithelial cells and non-
neoplastic cell, collectively referred to as “tumor stroma”. The tumor stroma, which in some 
carcinomas makes up more than 80% of the tumor mass, is composed of blood and lymphatic 
endothelial cells, infiltrating immune cells, pericytes and specialized fibroblasts, termed 
cancer associated fibroblasts (CAFs), embedded in a network of extracellular matrix (ECM). 
During the past years, it has become increasingly evident that far from being a mere 
bystander, the tumor stroma participates in many of the processes that control tumorigenesis 
(1-3). Cancer associated fibroblasts, which are the main source for extracellular matrix 
degrading enzymes, including cysteine-, serine-, and matrix metalloproteinases where shown 
to act as key players in remodeling the tumor microenviroment and to be essential for the 
local spread of tumor cells into the adjacent normal tissues and the formation of distant 
metastasis (4)(5). However, the molecular characteristics that distinguish a normal “resting” 
fibroblast from a cancer associated or “activated” fibroblast remain poorly defined. Presently, 
CAFs are defined by morphological characteristics and by the expression of specific sets of 
markers including fibroblast activation protein alpha (FAPα) (6), alpha-smooth-muscle actin 
(α-SMA) (7), fibroblast-specific protein 1 (FSP1/S100A4) (8) or PDGFRβ (9).This molecular 
heterogeneity has been linked to the diverse origin of CAFs, which have been reported to be 
derived from resident local fibroblasts, from bone-marrow derived progenitor cells or from 
transformed epithelial cells which have undergone an epithelial-to-mesenchymal transition 
(EMT) during tumorigenesis (10)(11). An increasing number of translational studies have 
recently emphasized the prognostic significance of different CAF-related molecular signatures 
(12)(13) and clinical studies targeting CAFs in human cancers have been proposed (14-16). 
We have used immuno-laser capture microdissection (iLCM) (17) and whole genome 
Affymetrix GeneChip® analysis to obtain transcriptional signatures from the tumor cells and 
the activated tumor stroma that were compared with the expression profiles from normal 
colonic epithelium and normal fibroblasts, derived from the same patients. Induced genes 
included several members of the Wnt-signaling pathway or collagen cross-linking enzymes 
such as lsyl oxidases. Moreover, increased expression of gene sets related to hypoxia, 
epithelial-to-mesenchymal transition (EMT) and TGFβ pathway activation were found in 
CAFs vs. their normal counterparts. We have identified a putative TGFβ target gene (18), 
IGFBP7, as a tumor stroma marker of epithelial cancers that can act as a tumor antigen in 
mesenchyme-derived tumors such as fibrosarcomas. We could further show, that IGFBP7 




malignant epithelial cells with an EMT phenotype, whereas a tumor suppressor function was 




Materials and Methods 
Tissues & immuno-laser capture microdissection (iLCM) 
Human tumor samples from patients with colorectal cancer were obtained from the 
Department of Pathology, Medical University of Vienna; the samples were collected in 
accordance with the guidelines of the institutional ethics committee. Matched pairs of tumor 
and normal colonic mucosa were snap frozen within 30 min after surgical resection. Five µm 
sections were stained with H&E to assess tissue preservation and for histopathological 
evaluation. The samples were analyzed for their expression of fibroblast activation protein 
alpha (FAPα) followed by laser capture on a PixCell IIe System (Arcturus Engineering Inc., 
Mountain View, CA) as previously described (17). 
RNA processing & global gene expression profiling 
Total RNA was extracted from the captured cells with the Arcturus Pico Pure RNA Isolation 
Kit (Arcturus Engineering Inc., Mountain View, CA) and amplified and labeled with the 
MassageAmpTM II-Biotin Enhanced Kit (Ambion, Austin, TX). Fragmented aRNA (15 µg) 
was used for hybridization of the Human Genome U133 Plus 2.0 GeneChip© arrays 
(Affymetrix, Santa Clara, CA). The arrays were hybridized and scanned using standard 
Affymetrix protocols. Microarray data were normalized using the Robust Multi-Array 
Analysis as implemented in Bioconductor (19)(20). All analyses were performed with log2- 
transformed data. Hypothesis tests were performed using a modified t statistics with an 
empirical Bayes approach as implemented in Bioconductor LIMMA package (21). P-values 
were adjusted by the FDR method of Benjamini and Hochberg (22). For our gene set 
enrichment analysis we used two gene set collections from the Molecular Signature Database 
provided by the Broad Institute, namely the curated gene sets (C2) and the Gene Ontology 
(GO) gene sets (C5) (23). The core genes of statistically significant genes were used to 





For IGFBP7 stainings on paraffin sections the avidin-biotin complex (ABC) 
immunoperoxidase method was used as previously described (6). Epitope retrieval was 
carried out in poteinase K solution (20 µg/ml in TE Buffer; pH 8.0).The primary goat anti-
IGFBP7 antibody was obtained from R&D Systems, Minneapolis, MA, Cat. # AF 1334 and 
used at 0.5µg/ml. Co-localization studies were done on acetone/methanol fixed frozen 
sections or chamber slides by double immunofluorescence methods. The following antibodies 
were used: monoclonal antibody F19 1:50 (6), monoclonal antibody H572 1:20 (24), rabbit 
anti-podoplanin 1:1000 (25), goat anti-NG2 (R&D Systems) 1:100, monoclonal antibody V9 
mouse anti-vimentin (Invitrogen, Carlsbad, CA) 1:1000, rabbit anti-β-Catenin 1:1000 (ab6302 
Abcam,Cambridge, UK)  Detection was performed with the following secondary antibodies: 
Alexa Fluor© 594 donkey anti-goat; Alexa Fluor© 594 goat anti-rabbit and Alexa Fluor© 488 
goat anti-rabbit from Molecular Probes (Invitrogen). 
Generation of stable IGFBP7/E-Cadherin knock-downs 
For shRNA mediated IGFBP7 knock-down we obtained five constructs (TRC0000077943 to 
TRC0000077947 in pLK0.1) developed by the the RNAi consortium (TRC) from Open 
Biosystems (Thermo Fisher Scientific, Waltham, MA). The constructs were packaged into 
lentiviral particles using a 2nd generation packaging system (Invitrogen) and used to infect the 
following cell lines HT1080, Caki-1 or SW480 (ATCC numbers: CCL-121, HTB-46, CCL-
228). 2 x 104 cells were seeded into a 24-well plate and incubated with full medium 
containing 5µl of the virus concentrates and 8µg/ml hexadimethrine bromide (Sigma, St. 
Louis, MO). To stably knock-down E-Cadherin in DLD-1 cells (CCL-221), we obtained 
SMARTvector 2.0 lentiviral particles from Dharmacon (Thermo Fisher Scientific) and used 
them according to the manufacturers´ instructions. For all constructs and cell lines, selection 
was carried out with puromycin (Invitrogen) at 1µg/ml final concentration. All work was done 





IGFBP7 Lentifect TM lentiviral particles were obtained from GeneCopoeia, Rockville, MD to 
overexpress the protein in DLD-1 cells. The infection and selection process was carried out as 
described in the previous section. 
Realtime PCR 
Total RNA was extracted using the Qiagen RNeasy® Mini Kit (Qiagen Hilden, Germany) 
following the manufacturers´ instructions. First strand cDNA was synthesized with an input of 
2µg total RNA using the Applied Biosystems´ High-Capacity cDNA Reverse Transcription 
Kit (Applied Biosystems, Carlsbad, CA). TaqMan probes and primers for IGFBP7 and 
GAPDH were obtained from Applied Biosystems. TaqMan PCR was done with an ABI 
PRISM 7000 Sequence Detection System (Applied Biosystems) according to the 
manufacturer’s instructions. The relative expression of IGFBP7 mRNA was normalized to the 
amount of GAPDH in the same cDNA using the comparative CT method described by the 
manufacturer.  
Immunoblotting  
Conditioned media obtained from Caki-1, HT1080, SW480, LS174T (CL-188), HT-29 (HTB-
38) and DLD-1 cells was concentrated with a centricon centrifugal filter device (Millipore, 
Billerica, MA) and used for IGFBP7 detection by immunoblotting. For all antigens, SDS gel 
electrophoresis was carried out on precast 4-12% gels (Biorad, Hercules, CA) under reducing 
conditions. The blotted membranes were blocked with 20% FCS in TBS-T for 1 hour at RT. 
Incubation with the appropriate primary antibody (anti-IGFBP7 0.1µg/ml; V9 mouse  anti-
vimentin 1:10.000; Abcam, HECD-1 mouse anti-E-Cadherin 1:1000; Bethyl Laboratories, 
Montgomery, TX rabbit anti-matriptase 1:1000; Trevigen, Gaithersburg, MD rabbit anti-
GAPDH 1:25.000) in blocking buffer (20% FCS in TBS-T) was carried out at 4°C overnight. 
The corresponding secondary HRP-conjugated antibodies (JacksonImmunolabs, West Grove, 
PA) were applied at 1:2500 in blocking buffer for one hour at RT. Immunoreactive signals 
were detected with the ECLplus system (GE Healthcare, Chalfont St. Giles, UK) and the 




Assessment of cell proliferation by in-vitro EdU labelling 
For proliferation analysis, HT1080 cells were grown to 50% confluence and then pulsed for 
30, 120 and 240 min. with 10µM EdU (5-ethynyl-2'-deoxyuridine, Invitrogen, Carlsbad, CA). 
Cells were then harvested and processed according to the manufacturers´ instructions (Click-
iT® EdU Alexa Fluor® 647 Flow Cytometry Assay Kit, Invitrogen). Flow cytometric data 
acquisition was performed on a FACSCalibur (BD Biosciences, San Jose, CA) and collected 
data were analyzed using FlowJo software 8.8.4 (Tree Star, Ashland, OR). 
Soft agar colony formation assay 
Anchorage-independent cell growth was analyzed using the colony formation assay in soft 
agar culture. Single cells were suspended in standard medium containing 0.4% (w/v) low-
melting agarose (Invitrogen) and platted at a cell density of 3 x 104 cells/dish on solidified 
1.2% agar-containing medium in six well plates. After 14 days of incubation, the cell colonies 
were fixed in acetone/methanol and stained with 0.005% crystal violet. The stained cell 
colonies were photographed and counted with ImageJ. 
Xenografts  
HT1080 cells were harvested and suspended in PBS/1% BSA. 100 µl of the cell suspension 
containing 108 cells was injected into the flanks of SCID mice (Charles River, Wilmington, 





Cancer-associated fibroblasts (CAFs) show increased expression levels of genes related 
to hypoxia, epithelial-to-mesenchymal transition (EMT) and TGFβ pathway activation. 
For our iLCM screen we analyzed a set of colon cancer samples together with their 
normal counterparts and captured the tumor cells, the tumor stroma as well as the normal 
stroma from these specimens (Supplementary figure 1). RNA extracted from the captured 
cells was processed for whole genome Affymetrix GeneChip® hybridization. After 
normalization and bioinformatic analysis, the three compartments (tumor cells, tumor stroma 
and normal stroma) could be clearly separated by unsupervised hierachical cluster analysis 
(Fig. 1A) and principal component analysis (data not shown). 1299 genes were differently 
expressed between the tumor stroma and the normal stroma, with 627 of these genes 
significantly up-regulated in the tumor stroma (false discovery rate p<0.01). Among the genes 
up-regulated in the tumor stroma vs. normal stroma were well established tumor stroma 
markers such as PDGFRβ, FGFR1, MMP2 or FAPα, the marker used to capture the activated 
fibroblasts from the tissue samples (Fig. 1B). Interestingly, induced genes included several 
members of the Wnt-signaling pathway such as secreted frizzled-related protein 2 (SFRP2), 
WNT2, WNT5a or Wnt-1 induced protein 1 (WISP-1). The up-regulation of WISP-1 and its 
putative binding partner biglycan (BGN) on the RNA and protein levels were confirmed in 
validation assays performed in independent colorectal cancer samples (Fig. 1B). 
For the further identification of tumor stroma specific genes sets we used the gene set 
enrichment analysis (GSEA) with two gene set collections derived from the Molecular 
Signature Database (Broad Institute); c2, the curated-gene sets, and c5 the gene ontology 
(GO)-gene sets (23). Among the GO datasets most significantly enriched (fdr q<0.25) were 
gene sets involved in response to wounding, extracellular matrix deposition, inflammatory 
response, cell migration, cytokine activity, cell-matrix adhesion, and vascular development 
(Fig. 1A, right). In addition, we identified 192 significantly enriched curated gene sets, 
including gene sets related to hypoxia, epithelial-to-mesenchymal transition (EMT), IL-6 and 
TGFβ pathway activation (Table 1).  
Enriched hypoxia related gene sets contained angiogenic growth factors such as VEGFC or 
angiopoetin-like 4 (ANGPTL4). Other genes in that category encoded collagens (COL1A2, 
COL4A1, COL5A1, COL9A1 and COL18A1) and their modifying enzymes (lysyl oxidase 




compartment undergoes multiple hypoxia-induced changes. Interesting examples for enriched 
genes related to IL-6 treatment comprised several pro-inflammatory cytokines such as 
CXCL3 or IL-6 itself. IL-6 is induced in large quantities during the transition from 
inflammatory response to early wound healing and is especially up-regulated by fibroblasts 
involved in fibrosis, associated with diseases such as rheumatoid arthritis (26). Gene sets 
involved in EMT included the mesenchymal marker N-Cadherin (CDH2), several tumor 
promoting matrix metalloproteinases such as MMP2 and MMP12 as well as extracellular 
matrix proteins implicated in invasion and metastasis such as tenascin C (TNC), laminin B1 
(LAMB1) or secreted protein acidic and rich in cysteine (SPARC). Many of the EMT related 
genes were also found among TGFβ induced gene sets, together with genes encoding fibrillar 
collagens (COL1A1, COL1A2, COL3A1 and COL5A2) and members of the insulin-like 
growth factor binding proteins family, such as IGFBP3 and IGFBP5. Another putative TGFβ 
target (18), IGFBP7, has appeared as one of the most significantly induced tumor stroma 
markers in our screen (tumor stroma vs.normal stroma, p< 2,14E-05) (Fig.2A). 
IGFBP7 is a tumor stroma marker of activated fibroblasts and endothelial cells in 
epithelial cancers. 
Immunohistochemical studies in tissue samples from colorectal cancer showed 
selective expression of IGFBP7 in tumor-associated vessels and in subsets of activated 
fibroblasts in the tumor stroma. Stainings performed in a variety of epithelial cancers revealed 
that IGFBP7 is frequently induced in the stromal compartment of solid tumors including 
samples of colon, NSCLC, pancreatic, ovarian and breast carcinomas (Fig. 2B). In none of the 
cases analyzed IGFBP7 was observed in the tumor cells. In contrast, IGFBP7 was expressed 
in the tumor cells as well as in the tumor stroma of soft tissue sarcomas, particularly in the 
tumor associated vasculature (Fig. 2B). This pattern of expression closely resembles that of 
two other tumor-stroma markers FAPα and Endosialin previously identified by our group. In 
double-labeling studies IGFBP7 co-localized with EndoGlyx, a marker for blood vascular 
endothelial cells (24) and the pericyte marker NG2 (27), indicating that IGFBP7 is a marker 
of endothelial cells and the surrounding mural cells. To further characterize and to ascertain 
whether IGFBP7 is a marker of blood (BECs) or lymphatic endothelial cells (LECs), we have 
tested primary BECs and LECs isolated from human dermal microvascular endothelial cells 
(HDMECs) for IGFBP7 expression. IGFBP7 was present both in BECs and LECs as 
demonstrated by its co-expression with CD31 and Prox1 (Fig.3A). As expected from the 




term culture were shown to express IGFBP7 and vimentin, a marker of mesenchymal 
differentiation (Fig. 3A). 
IGFBP7 is expressed by malignant mesenchyme-derived cells and malignant epithelial 
cells with a mesenchymal phenotype and promotes anchorage-independent growth in 
these cells. 
IGFBP7 expression was observed in malignant mesenchymal cells in soft tissue 
sarcomas by immunohistochemistry (Fig. 2B) and was further confirmed by Western blotting 
analysis on a panel of selected cell lines including the fibrosarcoma cell line HT1080 (Fig. 
3B). Moreover, high expression of IGFBP7 was observed in cancer cell lines, which have 
undergone EMT such as Caki-1 and SW480 cells. Colon cancer cell lines, which maintained 
the epithelial phenotype such as LS174T, HT29, DLD-1 lacked IGFBP7 expression (Fig. 3B). 
Expression of E-Cadherin and vimentin was used to characterize the phenotype of the cell 
lines included in the study (Fig. 3B). To establish the potential role of IGFBP7 in malignant 
mesenchyme-derived cells and epithelial tumor cells after EMT, IGFBP7 shRNA mediated 
knock-down experiments were carried out. In HT1080 cells, shRNA mediated knock-down of 
IGFBP7 resulted in >90% reduction on the protein level (Fig. 3C). The IGFBP7 knock-down 
had no effect on cell proliferation in 2D-cultures as demonstrated by an EdU incorporation 
assay (Supplementary figure 2). In a further next step, we analyzed the anchorage independent 
growth of the IGFBP7 knock-down and control cells by comparing their ability to grow and 
form colonies in soft agar culture. Intriguingly, the number of colonies growing anchorage 
independently after two weeks in soft-agar culture was significantly reduced after IGFBP7 
depletion in HT1080, Caki-1 and SW480 cells (Fig. 3D and data not shown). The ability of 
mammalian cells to proliferate anchorage independently often correlates with their ability to 
form tumors in vivo. In line with this, we have shown a delayed tumor take of the IGFBP7 
knock-down cells compared to the control cells at day 14 after implantation in a xenograft 




Proteolytically cleaved IGFBP7 reduces the anchorage-independent growth ability of 
epithelial tumor cells. 
To examine how IGFBP7 affects the anchorage-independent growth abilities of 
epithelial tumor cells, we overexpressed the protein in DLD-1 cells. These cells were shown 
to express E-Cadherin and to lack endogenous IGFBP7 expression (Fig. 3B). We compared 
the abilities of mock and IGFBP7 transfected DLD-1 cells to form colonies in soft agar 
culture. As demonstrated in Fig. 4A, DLD-1/IGFBP7 cells formed far fewer colonies than 
DLD-1/mock cells. Conditioned medium derived from the overexpressing cells showed two 
IGFBP7 bands representing a native 33 kDa form and a 26 kDa form, which previously has 
been reported to result from proteolytic cleavage by the type II transmembrane serine protease 
matriptase (MT-SP1) (28). Matriptase is present in several differentially processed intra- and 
extracellular forms and, as demonstrated by Western blotting, is expressed at high levels in 
the epithelial-type DLD-1 and HT-29 cells (Fig. 4B).  
IGFBP7 expression is induced in DLD-1 cells following E-Cadherin knock-down. 
Our results indicate that IGFBP7 secreted by activated tumor fibroblasts and tumor 
endothelial cells might function as a tumor suppressor on epithelial tumor cells during the 
early stages of tumorigenesis and as a promoter of tumor growth when the tumor cells have 
acquired a mesenchymal phenotype as a result of EMT. To further substantiate this 
hypothesis, we examined whether the loss of E-Cadherin, which was previously shown to 
induce EMT (29), leads to an induction of IGFBP7 expression. Therefore we knocked-down 
E-Cadherin in DLD-1 cells via stable shRNA expression. High knockdown efficiency was 
verified by Western blotting. Phenotypically, the E-Cadherin knock-down cells displayed a 
more mesenchymal phenotype in comparison to the control cells. In addition, we could 
demonstrate a redistribution of β-Catenin protein from the cytoplasma membrane to the 
nucleus, indicating β-Catenin activation in the cells lacking E-Cadherin. Most importantly the 
induction of the mesenchymal phenotype correlated with a significant induction of IGFBP7 






We have analyzed the molecular differences between CAFs and normal resting 
fibroblasts described by generating gene expression signatures from microdissected colon 
cancer and corresponding normal tissues. Among well-characterized tumor stroma markers, 
that served as validation parameter for our screen, several members of the Wnt-signaling 
pathway such as WISP-1, WNT2 or WNT5a appeared up-regulated in the stromal 
compartment. WISP-1 (Wnt-1 induced secreted protein 1) has recently been demonstrated to 
be induced in the tumor stroma in a paracrine fashion by Wnt-1 released by the tumor cells 
(30)(31) and to bind biglycan on the fibroblast surface (32). WNT5a, a gene involved in the 
non-canonical Wnt signaling, was induced in fibroblasts during co-cultivation with a 
pancreatic carcinoma cell line, suggesting that it could contribute to the strong desmoplastic 
reaction commonly found in this type of tumor (33). Thus, cancer associated fibroblasts could 
be regarded as primary candidates for locally modulating Wnt/β-Catenin signaling, which 
may result in heterogeneous patterns of β-Catenin intracellular localization observed within 
colorectal tumors (34). 
Tumor stroma specific gene sets related to hypoxia contained several collagens and their 
modifying enzymes, such as lysyl oxidase (LOX) and lysyl oxidase-like 2 (LOXL2). Lysyl 
oxidase is a copper-dependent amine oxidase that initiates the process of covalent intra- and 
intermolecular cross-linking of collagens (35). Collagen cross-linking by lysyl oxidase has 
recently been identified as a critical regulator of desmoplasia implying that the nature and 
level of ECM cross-links could impact cancer risk and alter tumor behavior (36). 
Interestingly, LOXL2 has also been observed in a “wound response signature” of fibroblasts 
in response to serum stimulation. Using independent datasets from human cancers, it has been 
shown that this “wound-response signature” was strongly predictive of metastasis and 
progression in breast, lung and gastric cancers and was an independent predictor of outcome 
in a follow-up study in breast cancer (12). 
In the TGFβ induced gene sets several members of the insulin-like growth factor binding 
proteins family, including IGFBP3, -5 and -7 were present. IGFBP3 up-regulation in the 
tumor stroma of prostate cancers has recently been demonstrated by global gene expression 
profiling following LCM (37) and a role as mediator for tumor - stroma interactions has been 
suggested in this type of tumors (38). Both IGFBP3 and -5 have been implicated in matrix 




transformation. Moreover, IGFBP3 has been recently shown to increase drug tolerance of 
tumor cells by promoting IGF-1R signaling (40). 
IGFBP7 belongs to a group of low-affinity IGF binders, which have been implicated in 
diverse biological roles independent of their ability to bind IGF. Numerous studies 
demonstrated their direct association with a variety of extracellular and cell surface molecules 
with effects on cell proliferation and adhesion (41)(42). IGFBP7 knock-out mice showed 
significant changes in ovaries, muscle tissues and liver even though the mice were viable (43). 
Secreted IGFBP7 protein is a cell adhesive glycoprotein, which is regulated by proteolytic 
cleavage into a two-chain form by a membrane-bound serine protease matriptase (MT1-SP1) 
(28). Because IGFBP7 is expressed in blood vessels of various human cancer tissues 
including colon cancer, it is also referred to as “angiomodulin” (44)(45). Previously, it has 
been demonstrated that IGFBP7 serves as a selective biomarker for tumor-associated vessels 
in glioblastoma, that it is pro-angiogenic and induced by Smad-2 dependent TGFβ signaling 
(18). Apart from its expression in tumor vessels, variable IGFBP7 expression patterns have 
been reported in different tumor types and expression in tumor cells has been shown to be 
modulated by DNA methylation, retinoic acid and TGFβ (46)(47)(41). IGFBP7 might 
function as a secreted tumor suppressor (48)(46) and in this context, it has been shown that 
overexpression of IGFBP7 in a colon tumor cell line leads to a significant increase of cell 
adhesion to several substrates mediated by cell-bound IGFBP7 via syndecan-1 and to a 
reduction of anchorage independent growth (49). 
We have demonstrated that IGFBP7 is a tumor stroma marker for several epithelial cancers 
expressed in activated fibroblasts and tumor vessels. We provide first evidence that IGFBP7 
is both expressed in lymphatic as well as blood endothelium in human carcinomas. 
Furthermore we demonstrate for the first time that IGFBP7 is selectively expressed in 
malignant mesenchyme-derived tumor cells. In these mesenchyme derived cells and epithelial 
tumor cells, which have acquired a mesenchymal phenotype by undergoing EMT, IGFBP7 
promotes anchorage-independent growth. Moreover, we could show that IGFBP7 reduces 
anchorage-independent growth when overexpressed in tumor cells with an epithelial 
phenotype (DLD-1) and that in those cells IGFBP7 is  cleaved to its to chain form. The 
proteolytic processing of IGFBP7 by the type II transmembrane serine protease matriptase 
was previously shown to greatly reduce its insulin ⁄ IGF-dependent growth promoting activity 
and to enhance its syndecan-1-mediated cell adhesion activity (50). Matriptase is a type II 
transmembrane serine protease and in striking contrast to FAPα it is a strictly epithelial 




a specific function in epithelial carcinogenesis (51). Thus, IGFBP7 secreted by activated 
fibroblasts or endothelial cells might be cleaved by matriptase on the surface of epithelial 
cells and then act as a tumor suppressor by reducing the anchorage-independent growth ability 
of these cells, whereas uncleaved IGFBP7 could enhance the growth of mesenchymal cells or 
cells undergone EMT through its insulin ⁄ IGF promoting activity. IGFBP7 may therefore act 
as tumor suppressor during early stage tumorigenesis and as a promoter of tumorigenesis, 
when tumor cells have acquired a mesenchymal phenotype by undergoing EMT. Supporting 
this model, we could demonstrate that IGFBP7 expression is induced in DLD-1 E-Cadherin 
knock-down cells. These results are corroborated by previous results which demonstrated the 
induction of IGFBP7 following E-Cadherin knock-down in a breast cancer model sytem (29). 
In that study it was further shown that neither the overexpression of a dominant negative form 
of E-Cadherin nor an E-Cadherin /β-Catenin double knock-down led to an increase of 
IGFBP7 expression, implying that this induction depends on the adoption of a mesenchymal 
cell state via the β-Catenin pathway. 
In conclusion, we could demonstrate the feasibility of our iLCM for the identification of 
tumor stroma targets such as IGFBP7. To further pursue the characterization of these newly 
identified targets, we have recently developed a novel 3D in vitro co-culture system (Dolznig H 
et al. manuscript in preparation). In combination, these approaches may provide new genetic 
markers in the tumor stroma, which may serve as novel targets for anti-cancer therapy. 
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Genes and gene-sets induced in the tumor stroma. (A) Unsupervised hierarchical cluster 
analysis of tumor cell, tumor stroma and normal stroma samples. 1299 genes were 
differentially expressed between the tumor stroma and the normal stroma. Heat map colors 
represent mean-centered fold change expression in log-space. (A, right) Gene-Set Enrichment 
Analysis (GSEA) revealed gene sets involved in response to wounding, extracellular matrix 
deposition, inflammatory response and cell migration significantly induced in the tumor 
stroma. The numbers of enchriched genes in each category are represented in a pie chart. 
(B) Well characterized tumor stroma markers such as FAPα , biglycan or Wisp-1 were found 
to be significantly induced  in the tumor stroma compartment vs. the normal stroma. The 
expression levels are indicated by whisker box plots, the bold centre-line indicates the 
median; the box represents the interquartile range (IQR). Whiskers extend to 1.5 times the 
IQR. TC, tumor cells; NS, normal stroma; TS, tumor stroma. Immunohistochemical stainings 
demonstrate the induction of these genes at the protein level (inserts).  
Figure 2. 
Induction of IGFBP7 in the tumor stroma. (A) The whisker box plot shows the induction of 
IGFBP7 in the tumor stroma (TC, tumor cells; NS, normal stroma; TS, tumor stroma). (B) As 
demonstrated by immunohistochemical staining on representative examples of colon and lung 
carcinomas, IGFBP7 is expressed in cancer associated fibroblasts and tumor vessels in those 
epithelial cancer samples. In soft tissue sarcomas, such as MFH (malignant fibrous 
histiocytoma), IGFBP7 is expressed by the malignant mesenchyme-derived cells. Paraffin 
sections were stained with the avidin-biotin immunoperoxidase (ABC) method and 
counterstained with haematoxylin (blue) 
Figure 3. 
IGFBP7 is a tumor stroma marker in epithelial cancers and a marker for malignant 
mesenchyme-derived tumor cells . (A) Double-labeling studies with EndoGlyx and NG2 
(green) on a colon adenocarcinoma section, demonstrating that IGFBP7 (red) is expressed by 




human dermal microvascular endothelial cells (HDMECs) and freshly isolated colon cancer 
associated fibroblasts (CAFs) are shown to be positive for IGFBP7. CD31, Prox1 and 
vimentin were used as established markers to characterize the individual cell types. (B) As 
demonstrated by Western blotting, IGFBP7 is expressed by malignant-mesenchyme derived 
cells (HT1080) and epithelial cells with a mesenchymal phenotype (Caki-1, SW480), whereas 
tumor cells with an epithelial phenotype (LS174T, HT29,DLD-1, Colo205) are IGFBP7 
negative. E-Cadherin and vimentin were used as markers to determine the phenotype of the 
cell lines. GAPDH was used as a loading control. Soluble IGFBP7 was detected in the 
supernatant (SN), vimentin, E-Cadherin and GAPDH in the corresponding cell lysates. (C) In 
HT1080 cells, shRNA mediated knock-down resulted in a significant IGFBP7 protein 
reduction in the supernatant. (D) As illustrated with a colony formation assay in soft agar, 
IGFBP7 knock-down results in a significant reduction of anchorage independent growth of 
HT1080 and Caki-1 cells. Colonies were stained with crystal violet and counted with ImageJ, 
the graphs represent the average results of three independent experiments.  
Figure 4. 
Proteolytically cleaved IGFBP7 reduces the anchorage-independent growth ability of 
epithelial tumor cells. (A) Soft agar colony formation assays shows a significant reduction of 
anchorage-independent growth of DLD-1 cells overexpressing cleaved IGFBP7, when 
compared to the mock transfectants. Colonies were stained with crystal violet and counted 
with ImageJ, the graphs repesent the average results of three independent experiments. (B) 
Conditioned medium from IGFBP7 overexpressing DLD-1 cells contained two IGFBP7 
bands, representing a native 33 kDa form and a 26 kDa form, which potentially results from 
proteolytic cleavage by matriptase (MT1-SP1). As indicated by Western blotting, type II 
transmembrane serine protease matriptase is a strictly epithelial protease, expressed by DLD-
1 cells at high levels. Soluble IGFBP7 was detected in the supernatant (SN) and GAPDH was 
used as a loading control and detected in the cell lysates. 
Figure 5. 
IGFBP7 expression is induced in DLD-1 cells following E-Cadherin knock-down. shRNA 
mediated E-Cadherin knock-down in DLD-1 cells results in significant protein reduction 
determined by Western blotting and a translocation of β-Catenin into the nucleus as shown by 




significant induction of IGFBP7 expression. The expression level of IGFBP7 was determined 
by realtime PCR relative to GAPDH. 
Supplementary figure legends 
Figure 1. 
Work flow for identification of novel tumour stroma markers by expression profiling 
analysis. The antibody-guided laser capture microdissection allowed the separation of 
epithelial cells from the activated stromal compartment in colon cancer samples. Activated 
tumor stromal fibroblasts were visualized by immunohistochemical staining with an antibody 
to FAPα . In the figure, the borders between epithelial and stromal structures are indicated by 
red dotted lines. Normal fibroblasts were isolated from normal colonic tissue after 
hematoxylin staining and morphological examination. After RNA isolation and amplification 
whole genome Affymetrix GeneChip® analysis was performed followed by bioinformatic 
evaluation to identify novel tumor stroma targets. Numbers and arrows indicate the numbers 
of genes and their change in transcript levels; red: up, green: down. 
Figure 2. 
Cell proliferation assays by Fluorescence Activated Cell Sorting (FACS). Cell proliferation 
assays were done with EdU (5-ethynyl-2´-deoxyuridine) incorporation and the DNA content 
was determined on the basis of fluorescence intensity for Propidium Iodide (PI). Plots display 
fluorescence intensity for EdU incorporation (Y-axis) and DNA content (X-axis) with colors 
representing increasingly higher number of cells with a given fluorescence intensity (orange, 
highest cell number; blue lowest cell number). After pulsing with EdU for 30 min, the fraction 
of EdUhigh HT1080 control and shRNA IGFBP7 cells was determined (41,4 vs.40,9%). 
Figure 3. 
Xenograft growth curves. Xenografts were established by injection of 1.107 HT1080 control 
and shRNA IGFBP7 cells in both flanks of SCID mice (n=3) and tumor growth was measured 
over a 14-day period. As indicated by the respective single and median tumor volumes, a 






In vitro phenotype resulting from E-Cadherin knock-down. In contrast to the control cells, 
which grew in monolayer culture as epithelial clusters, shRNA E-Cadherin knock-downs lost 








List of the most significantly enriched pathways sorted by the Normalized Enrichment Score 
(NES) using the c2 curated gene sets of genes upregulated in the tumor stroma. Size indicates 
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Activated tumor stroma participates in tumor cell growth, invasion and metastasis. Normal 
fibroblasts and cancer-associated fibroblasts (CAFs) have been shown to display distinct gene 
expression signatures. This molecular heterogeneity may influence the way tumor cells 
migrate, proliferate and survive during tumor progression. To test this hypothesis and to better 
understand the molecular mechanisms that control these interactions we have established a 
three-dimensional (3D) human cell culture system that recapitulates the tumor heterogeneity 
observed in vivo.  
Human tumor cells were grown as multicellular spheroids and subsequently co-cultured with 
normal fibroblasts or CAFs in collagen-I gels. This in vitro model system closely mirrors the 
architecture of human epithelial cancers and allows the characterization of the tumor cell-
stroma interactions phenotypically and at the molecular level.  
Using GeneChip analysis, antibody arrays and ELISA assays, we demonstrate that stromal 
fibroblasts induced different highly relevant cancer expression profiles. Genes involved in 
invasion, ECM remodeling, inflammation and angiogenesis were differentially regulated in 
our 3D carcinoma model.  
The modular setup, reproducibility and the robustness of the model make it a powerful tool to 
identify target molecules involved in signaling pathways that mediate paracrine interactions in 
the tumor microenvironment and to validate the influence of these molecular targets during 





Carcinomas comprise about 90% of all human cancers, including lung-, colon-, breast- and 
prostate carcinomas, which together cause about 50% of all cancer deaths 1. They consistently 
develop as highly complex structures composed of genetically altered tumor cells, together 
with fibroblasts, endothelial cells, pericytes and inflammatory cells embedded in a matrix of 
extracellular proteins (ECM). The tumor stroma influences the development of malignant 
tumors 2-4, for example the recruitment of blood vessels is ultimately required for tumor 
growth 3, 5. Fibroblasts comprise the major cellular component of the stroma of carcinomas. 
These cancer associated fibroblasts (CAF) have been shown to stimulate tumor progression of 
initiated non-tumorigenic prostate epithelial cells 6, and to promote the growth of breast and 
colon cancer in animal models 7,8. Recently it was demonstrated that the interaction of colon 
cancer cells with stromal cells activates the beta-catenin pathway in the cancer cells and led to 
an increase in colon cancer stem cells 9. Therefore, understanding the molecular mechanisms 
involved in the paracrine interactions between the tumor and the surrounding stroma will help 
to identify new molecules that may serve as potential drug targets. 
The culture of cells on two dimensional (2D) surfaces has provided groundbreaking insights 
into basic cell biology and tumorigenesis 10,11,12. However, most physiological parameters of 
organs or tumors such as tissue architecture, cell to cell- and cell to matrix interaction, 
mechanical properties and biochemical networks are lost under these simplified conditions. 
Cells grown in three-dimensional (3D) scaffolds or as 3D aggregates (multicellular spheroids) 
much better recapitulate the in vivo situation of tissues 13-15 or tumors 16-21. These 3D culture 
systems were rarely used to address the mechanisms of interaction between human tumor-and 
stromal cells embedded in ECM 22-24. 
We have combined well-established 3D cellular assays (multicellular spheroids, 3D collagen 
gel cultures, co-cultures) into one experimental setup, which we call the “in vitro carcinoma 
assay”. We show that this model system is physiologically relevant and allows live imaging, 
histological examination, biochemical assays and functional experiments to be performed in 
parallel. In addition, expression-profiling analysis identified genes differentially regulated 
upon tumor stroma interaction, which are relevant for carcinogenesis. Finally, we demonstrate 





Multicellular tumor spheroid – fibroblast co-culture experiments in a 3D collagen gel 
matrix 
Seventeen human tumor cell lines were tested for their ability to grow as multicellular 
spheroids. Eleven cell lines formed spheroids, whereas six cell lines only formed loose cell 
aggregates under any of the experimental conditions tested. Spheroids from different cell lines 
behaved differently when placed into collagen gels. Some remained as compact spheres and 
did not show signs of invasion; others displayed moderate invasion, and other cell types such 
as SK-OV-3 showed extensive invasive structures characterized by multicellular astral 
outgrowth into the collagen gels (Figure 1A, Supplementary Table 1 and Supplementary 
Figure 1). 
The colon cancer cell line LS174T, defined as non-invasive in our assay, was selected for 
further studies. LS174T spheroids were prepared, harvested and mixed with freshly 
trypsinized fibroblasts (Supplementary Material and Supplementary Figure 1). The mixture 
was centrifuged and the pellet resuspended in collagen I solution and poured into silicone 
moulds (Figure 1B). This gave rise to flat collagen gel-cylinders, which were mechanically 
stabilized by submerging nylon mesh rings before polymerization (Figure 1B, bottom). The 
gel-cylinders harbored either 96 tumor cell spheroids surrounded by 2x105 normal fibroblasts 
or CAFs. In addition tumor cell spheroids without fibroblasts or fibroblasts alone were 
prepared in a similar way. The fibroblasts used were normal embryonic colon fibroblasts 
(CCD18-Co, designated NCF), hTERT immortalized skin fibroblasts (BJ-1, designated SF) 
and primary fibroblast cultures isolated from human colon carcinoma specimen (cancer 
associated fibroblasts, CAF1, CAF2, Supplementary Figure 2).  
The ring-shaped nylon meshes facilitated the microscopic analysis by phase-contrast of living 
cells (Figures 1C, 2A, 8A+C) and by fluorescence-microscopy of labeled cells (Figures 5, 
Supplementary Figures 4, 5). When tumor spheroids and fibroblasts were cultured without the 
supporting nylon mesh, the free floating collagen gel cylinders shrunk and appeared as dense, 
refractive structures within 2-3 days due to the contractile forces of the fibroblasts in the gels 
as described 25, which hindered microscopic evaluation (Figure 1C). In contrast, embedded 
nylon meshes resisted the contracting force of the fibroblasts and completely abolished 





Phenotypic characterization and morphology of the tumor cell clusters 
In the presence of fibroblasts, LS174T tumor spheroids (Figure 2A) displayed well organized 
glandular structures after 24-48 hrs co-culture as revealed by transmission light microscopy 
and after H&E staining. The epithelial cells expressed the luminal tight junction protein ZO-1, 
predominantly membrane associated beta-catenin and secreted mucin into the glandular 
structures (Figure 2B). Electron microscopy revealed the characteristic intestinal cell 
microvillus seam at the luminal side on LS174T cells when grown alone or in the LS174T-
NCF co-cultures. Differences in the electron density of the mucus were observed when 
comparing LS174T spheroids cultured alone versus the co-cultures, probably indicating a 
different composition of the mucin (Figure 2C). Differences were also noted in the cell-cell 
interactions, with well established desmosomes, adherens-junctions and tight-junctions 
observed in the LS174T cells co-cultured with fibroblasts, which were less developed in 
LS174T cells grown alone (Figure 2D).  
Fibroblast-tumor cell interaction 
Fibroblasts, when added to the cultures, formed a well-organized network around the tumor 
cell spheroids within 2-3 days (Figure 3A, left), regardless of the source of fibroblasts. The 
fibroblasts expressed PDGFRbeta and when in vicinity of the LS174T spheroid were closely 
attached to the tumor spheroid surface (Figure 3A). Electron microscopy revealed close cell-
cell interactions between epithelial cells and fibroblasts in tumor spheroid/fibroblast co-
cultures (Figure 3B). Fibroblasts in the collagen gels, like in tissues, displayed spindle shaped 
morphology (Figure 2A, Figure 3C), which did not change upon co-cultivation with tumor 
cell spheroids. They expressed vimentin, alpha-smooth muscle actin (in subsets) and 
fibroblast activation protein alpha (FAP), a tumor stromal fibroblast marker 26, closely 
resembling activated fibroblasts in tumor stroma in vivo (Figure 3C). In summary, the in vitro 
cultures closely mimic the cellular architecture of human colon carcinoma samples at the 
histological level (Figure 3C).  
Co-cultivation experiments of other human cancer cells such as colon cancer (HCT116, HT-
29) and mammary tumor cell spheroids (MCF7, BT474) with CAFs displayed similar 
phenotypes with respect to their in vivo counterparts (data not shown), demonstrating the 




The in vitro system recapitulates major features of colon carcinomas in vivo 
Tumor cells within the spheroids were highly proliferative as shown by staining for 
phosphorylated retinoblastoma protein (phospho-Rb)27 similar to colon carcinomas in vivo 28. 
In contrast, co-cultured fibroblasts were predominantly quiescent, displaying very rare Rb 
phosphorylation (Figure 4A). These immunofluorescence results were confirmed by Western 
Blot analysis. The co-culture did not significantly change the phospho-Rb status of the cells 
(Figure 4A, right). When tumor spheroids grew beyond > 450 micrometer diameter they 
showed a ring of proliferating cells surrounding apoptotic/necrotic central areas 29 
(Supplementary Figure 4), mimicking in vivo observations 30. 
Subsequently,we analysed the status of the HGF-Met axis, which is one of the best-
characterized epithelial-stromal paracrine pathways. c-Met overexpression and paracrine 
activation by HGF, which is produced by stromal cells 31, has been implicated in colon cancer 
development, invasiveness and clinical outcome 32, 33. Using receptor-tyrosine-kinase arrays 
we showed that c-Met was tyrosine phosphorylated in the LS174T tumor cells, when 
incubated with conditioned medium (CM) from LS174T spheroid/fibroblast co-cultures, 
however c-Met was not phosphorylated when incubated with CM from tumor spheroid- or 
fibroblast mono-cultures (Figure 4a). On the other hand, HGF was selectively produced by the 
fibroblasts as demonstrated by cytokine array analysis (Figure 4a). This indicated a selective 
proteolytic activation of the HGF precursor in the co-cultures which is in line with the 
reported expression of an HGF activator (HGFA) protease by colon cancer cells 34.  
A recent report demonstrated that high Wnt pathway activity in colon adenocarcinoma cells 
was induced by the presence of stromal myofibroblasts both in vitro and in vivo. This 
paracrine stimulation of the Wnt pathway was accompanied by the induction of a cancer stem 
cell phenotype 9. A similar behavior was observed in our model. First, we observed a 
heterogeneous activation of the Wnt pathway on the LS174T spheroids as revealed by the 
staining with beta-catenin, a marker protein for Wnt pathway activation. In LS174T spheroids 
the majority of the cells displayed membrane bound beta-catenin, with only few cells showing 
nuclear beta-catenin localization (Figure 4C). When LS174T cells were co-cultivated with 
colon-derived fibroblasts (NCF and CAFs) the percentage of nuclear beta-catenin positive 
cells increased more than fivefold (Figure 4C, bottom, right), indicative of Wnt pathway 
activation via the stromal fibroblasts. Thus, we demonstrate that the in vitro assay closely 





Fibroblasts induced invasive spreading of LS174T cells 
LS174T cells were transfected with DsRed and stable clones were selected (LS174TdsR). 
LS174TdsR cell spheroids were embedded in collagen gels in the presence or absence of 
fibroblasts, incubated and followed by light- and fluorescence microscopy. After about 4 
days, the presence of fibroblasts in the cultures induced an invasive phenotype in the LS174T 
cells (Figure 5A). Collective and single cell invasion was observed by confocal imaging 
(Figure 5A, B) and time-lapse microscopy of fluorescently labeled tumor cells 
(Supplementary Figure 5). In contrast, LS174T cell spheroids in the absence of fibroblasts 
displayed a non-invasive phenotype in collagen gels even after 11 days in culture (Figure 5A, 
B). 
Expression profiling 
To further substantiate the suitability of the novel system for molecular analysis we 
determined changes in gene expression upon co-cultivation of tumor cells with stromal 
fibroblasts by GeneChip arrays. Ninety-six LS174T tumor cell spheroids and 2x105 
fibroblasts were cultured in collagen gels either separately or as co- cultures for 3.5 days 
(Supplementary Figure 6). We used SF, NCF and CAFs to reveal common and different 
responses induced by co-cultivation. Lysates from LS174T mono-cultures were mixed with 
fibroblast mono-culture lysates (designated as mono-culture mixed) thereby ensuring the 
same amount of tumor cells and fibroblasts present as in the co-culture experiments. All 
experiments were done in biological triplicates. We used a direct-lysis approach of the entire 
collagen gel cultures rather than isolating and sorting of cancer cells and fibroblasts to avoid 
changes in RNA expression during the isolation process (duration >1.5 hrs). RNA extracted 
from the mixed and the co-culture experiments was processed for whole genome Affymetrix 
GeneChip analysis (Supplementary Figure 6). After normalization and bioinformatics analysis 
(Supplementary Methods) we identified genes differentially regulated in co-cultures 
compared to cultures identical in the cellular composition but without physical contact during 
culture. In addition, co-cultivation of LS174T cells with fibroblasts of different origin allowed 
determining specific responses to the various fibroblast types. Principal component analysis 
(PCA) detected four clusters dependent on the fibroblasts present in the experimental setup, 
with the skin fibroblasts clustering apart from the colon fibroblast clouds (NCF, CAF1, 
CAF2). All co-culture clusters were shifted in the same direction close to the corresponding 
mix clusters (Figure 6A). 535 genes were differentially expressed in colon fibroblast co-




176 genes were regulated in the co-cultures with CAFs (134 up and 42 down; FC>1.5, fdr, 
p<0.01; Supplementary Figure 7A). 180 genes were differently expressed between colon 
derived- and skin fibroblasts (fdr, p<0.01, 96 up in skin fibroblasts, 84 up in colon derived 
fibroblasts), when compared under the mono-culture mix conditions.  
Pathway analysis 
Gene-Set Enrichment Analysis (GSEA35) was used to identify predefined gene sets regulated 
upon co-cultivation. We used two gene set collections from the Molecular Signature Database 
(Broad Institute 36), the c2 curated-gene sets, and the c5 GO-gene sets. Among the datasets 
most significantly enriched in the co-cultures were gene-sets involved in hypoxia, ras-
signalling, inflammation, extracellular matrix deposition, angiogenesis, tissue development, 
wound healing and EMT (Table 1, Supplementary Table 1). The core genes of statistically 
significant gene-sets were used to calculate PCA plots. A clear-cut segregation of the 
individual co-culture and the mixed-mono-culture experiments was evident for all gene-sets 
tested. Examples for activation of ras-oncogenic signaling (Figure 6B) and cell-cell-signaling 
(Supplementary Figure 7B) are shown.  
Pathway analysis (Ingenuity®) revealed similar gene-networks, e.g. linked to cancer, 
embryonic and tissue development, cell growth and proliferation, cell to cell signaling, 
immune response, being extensively regulated in tumor/stroma co-cultures (Table 1, 
Supplementary Table 2). A 35 gene network clustering around NF-kappa B displayed 
extensive regulation (Figure 6C). 11 genes were regulated by all fibroblast types, expression 
of 10 genes was changed by the presence of colon fibroblasts, whereas 8 genes were solely 
altered by CAFs. Expression profiles of selected genes are shown in Figure 7. CEACAM5 
encoding the diagnostically relevant carcinoembryogenic antigen (CEA) was most potently 
induced by colon CAFs, with intermediate induction by normal colon fibroblasts, whereas 
skin fibroblasts had no effect (Figure 7A, left panel). Elevated CEA protein levels in tumor 
spheroids co-cultured with CAFs validated the RNA expression data (Figure 7A, right panel). 
The induction of CXCL8 (IL-8) on the mRNA level upon co-culture with colon-derived 
fibroblasts (Figure 7B, left) was verified by ELISA in the respective culture supernatants. 
CXCL8 levels were low in LS174T cultures and were raised by a factor of two to 5-7 ng/ml in 
the co-cultures with colon-derived fibroblasts. LS174T spheroid/skin fibroblast co-cultures 
did not show a synergistic upregulation in concordance with the RNA data (Figure 7B, right).  
One of the most significantly regulated genes from the NF kappa B network was DMBT1 




culture (Figure 7C, left). Loss of DMBT1 in astrocytomas and in squamous carcinomas is 
well established and indicates that DMBT1 might be a tumor suppressor. However, in 
gastrointestinal carcinomas DMBT1 expression is transiently upregulated during 
tumorigenesis and decreased only in very dedifferentiated cancers 37, 38 and has been shown to 
be induced upon proinflammatory stimuli via the NF kappa B pathway 39. Using a large 
expression database (Affymetrix Exon Chip, BioExpress, GeneLogic) we could demonstrate 
that DMBT1 mRNA was present in normal colon and lung and absent or very weakly 
expressed in normal breast, prostate and thyroid gland. DMBT1 expression was significantly 
reduced in lung carcinomas, whereas colon cancer samples displayed increased DMBT1 
levels. In perfect correlation with the literature (see above), DMBT1 levels decreased in 
metastatic colon cancers. Breast, prostate and thyroid cancers were almost negative for 
DMBT1 mRNA (Figure 7C, right). The obtained data were confirmed in a different set of 
database using Affymetrix Plus GeneChip based BioExpress databases (Supplementary 
Figure 8A). Prominent upregulation of DMBT1 was also observed in stomach-, pancreatic-, 
esophagus-, and colon mucinous carcinomas when compared to the levels of the respective 
normal tissue counterparts (Supplementary Figure 8B). 
Monitoring tumor growth and apoptosis upon inactivation of the PI3K Pathway in the 
in vitro assay 
First, we determined the growth rate of the tumor spheroids by calculating the size of 
individual spheroids at different time points (Figure 8A). The mean size of 8-10 spheroids 
was calculated. The rate in tumor spheroid volume increase was similar whether fibroblasts 
were present in the cultures or not (Figure 8B). In order to demonstrate the applicability of the 
system for drug testing we treated the LS174T/fibroblast co-cultures with the PI3K inhibitor 
LY294002. Tumor cell growth was measured daily as described. In the presence of 
LY294002 the size of the spheroids increased 1.5 times during the observation period, 
whereas the untreated controls displayed a fivefold increase (Figure 8C). Fibroblast 
morphology or cell number did not change upon LY294002 treatment, indicating no or minor 
effects on the stromal compartment. Staining of sections with activated-caspase-3 antibody 
revealed 25 % apoptosis in tumor cell spheroids upon PI3K inhibition, whereas control 
cultures displayed an average apoptotic rate of <10% (Figure 8D). Activation of caspase-3 in 
the fibroblasts was detectable in 4% of the untreated- and in 3% of the treated cultures, 
indicating that the low apoptosis rate in fibroblasts was not affected by the inhibitor (Figure 




found to be reduced more than threefold upon treatment with LY294002 as compared to 
controls (Figure 8E). Phospho-H3 positive fibroblasts were not detected, indicating absent or 
very low mitotic activity. Representative IHC-stainings for those markers are shown in 






There is strong evidence that demonstrates the active role of the tumor stroma in 
tumorigenesis, however with only few exceptions the molecular mechanisms involved in the 
paracrine interactions between the tumor and the surrounding stroma remained poorly 
understood 40. This was probably due to the limitations of available in vitro-models to reflect 
the heterogeneous (cellular and molecular) composition of human cancers and the cellular 
complexity of animal models. 
Cellular heterogeneity and interaction in a 3D environment is not reproduced by standard 
tissue culture techniques on 2D surfaces. 3D in vitro models closely mimic features of the in 
vivo situation and provide unique possibilities to study the behavior of cancer 41. Organotypic 
3D co-culture models have been used to study the functional interplay between tumor cells 
and fibroblasts 18, 24, 42. Our “in vitro carcinoma assay” aims to further close the gap between 
conventional in vitro assays and the in vivo situation, because it innovatively combines 
spheroid cultures with collagen gel assays and heterotypic cell interactions. In a reductionist 
approach the in vivo cellular complexity was reduced to two cell types: the tumor cells and 
stromal fibroblasts, in order to get clear information about the specific molecular interactions 
of these cells during their growth in vitro. Additionally, we introduce other important features 
of the in vivo growth, the three-dimensionality achieved by using spheroids 3D cultures and 
by embedding the cellular components into a collagen I rich ECM matrix. The system is 
modular and offers the possibility to compare results from single component cultures with the 
co-cultures, thus allowing molecular screens to identify pathways, which are not active in 
mono-cultures but induced upon co-cultivation. In addition, it is possible to exchange the 
modules in the co-cultivation experiments or to even extend the cellular components in the 
co-cultivation screens to three or four cellular components (e.g. to add tumor associated 
macrophages or endothelial cells).  
In summary, we provide evidence that our model: i) Mimics the cellular architecture of 
human cancer tissues both histologically and phenotypically. ii) The invasive potential of 
colon cancer cells is induced in the co-culture system. LS174T cells displayed invasive 
behavior with features of collective cell migration as frequently seen in human carcinomas 43, 
when in contact with stromal fibroblasts (Figure 5). Fibroblast-led cancer cell invasion was 
recently shown to operate in invasive HNSQCC 24. iii) Molecular profiling of mono and co-
cultures can be used to characterize known and to identify novel pathways in tumor-stroma 




advantages for therapeutic studies can be envisioned. It has been shown that cancer cells 
grown as spheroids display multicellular resistance (MCR), which make them less susceptible 
to different therapies 44. Cancer cells in patients often display the same MCR, therefore the 
impact of MCR can be closely investigated pre-clinically in this model. The effect of stromal 
cells on tumor cells upon chemo- and radiotherapy can be addressed. Recent reports 
demonstrated decreased sensitivity of tumor cells to therapy when co-cultured with activated 
stromal fibroblasts 45, 46 and finally the effects of novel agents targeting the tumor stroma can 
be investigated in detail.  
The molecular analysis of the tumor-stroma interaction has revealed that the well-defined 
paracrine HGF/c-Met crosstalk and the activation of the Wnt pathway were recapitulated in 
our model. Comparison of the gene expression profiling in monocultures versus co-cultures 
revealed a number of pathways, which were selectively activated upon co-cultivation of tumor 
cells with CAFs. For example, the Ras signalling pathway or the NF-kappa B signaling 
pathway was altered upon co-cultivation with colon-derived fibroblasts (33 out of 36 genes 
regulated in the NF-kappa B network). The activation of NF-kappa B is associated with 
inflammation associated colon carcinoma and tumor progression 47. We provide first evidence 
for NF-kappa B activation by interaction of tumor cells with stromal fibroblasts. The NF-
kappa B target CXCL8 was specifically induced in co-cultures and may promote tumor 
growth, neutrophil activation, invasion and tumor angiogenesis as proposed 48-50. Since only 
human cells are used in the system, concerns about species specificity of cytokines and 
growth factors and their respective receptors (as it is the case in xenograft mouse models) can 
be neglected. At the moment– due to the technical setup of the screening procedure - we were 
not able to distinguish in which compartment certain pathways are regulated. A protocol to 
separate fibroblasts from tumor cells in the assay is currently under development (Dolznig, 
data not shown). Another NF-kappa regulated gene, DMBT1, plays a not well-defined role in 
carcinogenesis. DMBT1 functions as a tumor suppressor in many squamous epithelial cancers 
and in brain tumors, the role of DMBT1 in gastrointestinal cancers is less clear 38, 39, 51. 
DMBT1 was selectively induced by co-culture of cancer cells with CAFs and is upregulated 
in gastrointestinal cancers, whereas it seems to be non-relevant for prostate, breast and thyroid 
cancer development. The increase in DMBT1 expression in primary colon cancers and its 
downregulation in metastatic colon carcinomas points to an early role in tumorigenesis as 
already discussed in the literature. Taken together the involvement of many genes of the 
identified NF kappa B network in cancer makes this tumor-stroma interaction induced 




Both, Ras signalling and NF-kappa B activity are essential for epithelial mesenchymal 
transition (EMT). The EMT specific gene set was specifically enriched in the co-cultivation 
experiments, suggesting that epithelial-fibroblast interaction in colon carcinomas induces 
EMT by parallel activation of the ras pathway and the inflammatory NF-kappa B response 52, 
which can easily be addressed in the system in the future.  
Moreover, we could demonstrate that many gene sets (including ECM remodeling, EMT), 
which were regulated exclusively upon co-cultivation of LS174T tumor cells with CAFs, 
were also activated in an ex vivo screen, in which laser-capture-microdissected tumor stroma 
was compared to normal stroma from colon cancer patient samples (53 and Rupp et al, 
manuscript in preparation). The complementarities of the two approaches emphasized the 
relevance of the 3D co-culture model to dissect and to identify specific pathways involved in 
tumorigenesis. 
Novel molecular targets can be validated by genetically modifying the tumor cell 
compartment or the stromal cells in the system 54 and the functional relevance demonstrated 
in in vivo animal models. The possibility to compare the in vitro data with the data obtained 
from human material, linked to the fact that it is robust and highly versatile should allow the 
use of our model as an accurate tool for target identification/validation with the potential to 





Conventional methods on cell culture, immunohistochemistry, histochemistry, RNA isolation, 
real time PCR, Affymetrix GeneChip hybridisation and normalisation, GSEA, Western 
blotting, phospho-tyrosine kinase and cytokine arrays, and transmission electron microscopy 
are described in Supplementary Information. 
Spheroid formation 
Multicellular spheroids were generated essentially as published for endothelial cell spheroids 
55. In brief, tumor cells were grown on plastic, trypsinised, counted and resuspended in 
DMEM/5% serum containing 12mg/ml methylcellulose (Sigma, #0512). The cells were 
seeded into non-adhesive u-shaped 96-well-plates for suspension culture (Greiner, #650185) 
at a concentration of 150-200 cells per well. Compact multicellular spheroids were harvested 
after 2-3 days, washed and 96 tumor cell spheres each were transferred into 1.5 ml 
microcentrifuge tubes. Fibroblasts for co-culture experiments were cultivated on plastic in 
serum free fibroblast growth medium (FGM, Promocell). After trypsinisation, cells were 
counted; 2x105 cells were transferred into 1.5 ml tubes and centrifuged at 250 g. In case of co-
culture experiments the cells were centrifuged onto the previously prepared spheroid pellets. 
The entire supernatant was carefully removed and the cells / cell-spheroid pellets were kept 
on ice until further use. 
Collagen gel culture 
Gel casting devices were produced by cutting out 2 x 2 cm squares of a silicone foil (Gel 
dryer sealing gasket, Biorad, 1 mm thickness, #1651748) into which holes of 1.4 cm diameter 
were cut with a puncher. Nylon filters were prepared from the nylon mesh inserts of Medicon 
syringe filters (BD, 100 µm, #340612), of which a hole of 1 cm diameter was cut out in the 
centre. The silicone casting devices and the nylon meshes were autoclaved and placed onto 
the inside surface of lids of 10 cm cell culture dishes, where they firmly attached.  
For the collagen gel preparation all steps were performed on ice. Collagen solutions were 
prepared by mixing 0,2 ml of 10x PBS, 0,8 ml of FGM/20% Methylcellulose, 1 ml of 
Collagen I (rat, BD, 3.48mg/ml, #354236) and neutralized with 23 µl of 1M NaOH. The 
solution was mixed carefully; air bubbles were removed by centrifugation at 300g for 2 min. 
200 µl each of the collagen solution was transferred into the tubes containing the spheroid/cell 




the casting devices; a nylon filter was added and submerged. After polymerisation of the 
collagen solution for 30 min at 37°C/5% CO2 the silicone foil was removed, leaving collagen 
gel cylinders. The gels were transferred into 24 well plates containing 1 ml of FGM 
supplemented with 2.5% serum. The culture medium was replaced every second day and 
conditioned medium was kept, sterile-filtered and snap-frozen in liquid nitrogen. Celltracker 
Green CMFDA (Molecular Probes, Invitrogen, CatNr. C2925) was used for long term tracing 
of fibroblasts for live cell imaging as recommended by the supplier. The growth rate of the 
tumor spheroids was determined by calculating the mean volume of 8-10 spheroids, using the 
formula (length x width2 x /6) as used to determine the size of subcutaneous xenograft 
tumors in mice 56, 57. 
The TissueQuestTM software (TissueGnostics GmbH, Vienna) was used to quantify 
fluorescent photomicrographs. Cell detection is based on identification of nuclei by DAPI 
staining. Fluorescence intensity quantification was done independently in different channels. 
All photomicrographs were taken with the same settings (exposure time, signal amplification, 
objectives).  
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Experimental setup. (A) Examples of cancer cell line spheroids embedded in collagen gels. 
HCT116 cells were non-invasive, whereas SK-OV-3 cells formed invasive structures within 
24 hrs of cultivation. Caco-2 cells did not form spheroids. (B) Scheme of workflow. Spheroid 
formation was induced by seeding tumor cells in round-bottom shaped 96 well plates. After 2-
3 days tumor spheroids were harvested and resuspended in collagen I solution in the presence 
or absence of 2x105 normal colon fibroblasts. The suspension was transferred into a silicone 
casting mould and a ring-shaped nylon mesh was submerged. After collagen gel 
polymerisation, the mould was removed and the collagen gel was transferred into a 24 well 
plate and incubated with growth medium. (C) Contractile force created by fibroblasts shrunk 
collagen gels within three days. The embedded nylon mesh averted shrinking of the collagen 
gel. Dashed white circles highlight the outline of the gels (top). The contraction of the 
collagen gel hindered light microscopic morphological examination in non-supported gels at 




surrounding fibroblasts and ECM, whereas cells in nylon mesh reinforced collagen gels could 
be easily evaluated. The nylon mesh is visible as dark netlike structure (scale bar: 200 m).  
Figure 2 
Microscopic evaluation of the tumor cell spheroids. A Co-culture of LS174T spheroids with 
colon fibroblasts (LS174T+NCF) in collagen gels induced morphological changes in the 
tumor cell aggregates as compared to tumor spheroids cultured under the same conditions 
alone (insert: LS174T). At 2 days of co-cultivation hollow structures were clearly visible 
within the tumor spheroid (arrowheads, size bar: 200 m). B H&E staining of collagen gel 
sections revealed more frequent and bigger acinous structures (white areas inside the 
spheroids) in LS174T spheroids co-cultured with fibroblasts (LS174T+NCF). Glandular 
structures were filled with mucus as determined by PAS staining (magenta areas) and 
displayed full polarisation (ZO-1 staining in green, beta-catenin in red, blue: DAPI). C 
Transmission electron microscopy (EM) revealed that well-developed gland like structures 
with microvilli at their luminal side (L) were present in LS174T spheroids as well as in tumor 
spheroid/fibroblast co-cultures (LS174T + FB, top). Nuclei of tumor cells are labeled (N). 
Scale bars: 500 nm. D Junctional complexes containing desmosomes (D), tight junctions (T), 
and adherens junctions (A) were formed between LS174T tumor cells in the presence of 
fibroblasts (bottom), whereas LS174T spheroids alone displayed more rudimentary 
desmosomal structures (top). Interdigitations (I) and microvilli (MV) were present on LS174T 
cells under both conditions (scale bars: 200 nm).  
Figure 3  
Tumor cell spheroid-fibroblast interaction. A Confocal imaging of in gel immuno–
fluorescence staining. The left panel shows a superimposed 28 micrometer z-stack (vimentin 
in red, E-cadherin in green). Middle panel: PDGFRbeta positive normal colon fibroblasts 
(green) make close contacts to LS174T spheroids. The border of the spheroid is outlined 
(white dashed line). Right panel: Single plane confocal image of vimentin positive fibroblasts 
(red), which surrounded E-cadherin positive tumor spheroids (green). Nuclei were stained 
with DAPI (blue), (scale bar: 50 m). B Epithelial cells developed tight cell-cell contact with 
fibroblasts (F, encircled by dotted line) at the invasive structures (black arrowheads in insert, 
bottom) as revealed by EM. The inset is a higher magnification of the area indicated by the 
white lined rectangle. The orientation of the inset is indicated by a white triangle. Nuclei of 




stained the fibroblasts in the co-cultures (top) strikingly similar to activated fibroblasts in a 
human colon adenocarcinoma (bottom, scale bars: 200 m). H&E stains of LS174T spheroids 
plus NCFs in collagen gels after three days of culture display close cell-cell interaction and 
tumor cell heterogeneity. In the presence of NCFs condensed and restructured collagen fibres 
were present and fibroblasts were nestled around tumor epithelial cell islands in similar 
density and morphology as compared to a representative human colon carcinoma specimen 
(scale bars: 50 m). 
Figure 4 
Molecular pathway analysis. A Phosphorylated retinoblastoma protein (pRb, green), was 
predominantly found in tumor cell nuclei, whereas vimentin positive fibroblasts (red) were 
rarely positive for pRb. Nuclei were stained with DAPI (blue), (scale bars: 20 m). Western 
blots of collagenase B released cells confirmed the pRb status from the immunofluorescence 
analysis (right). B LS174T cells were starved for six hours and subsequently treated either 
with conditioned media from LS174T spheroid collagen cultures (LS-CM), fibroblast 
collagen gel cultures (NCF-CM) or LS174T/fibroblast co-cultures (LS/NCF-CM) for 15 min. 
Further starvation (starved) and treatment with fresh culture medium (medium) served as 
controls. After lysing the cells phospho receptor tyrosine kinase (pTyr) arrays demonstrated c-
Met phosphorylation in LS174T cells, when treated with conditioned medium from LS174T-
fibroblast co-cultures (LS/NCF-CM). c-Met was phosphorylated neither upon tumor cells nor 
in fibroblasts, when individually cultured in collagen gels (left, top). Cytokine arrays (left, 
bottom) revealed the presence of HGF in both tumor cell/fibroblast co-cultures as well as in 
fibroblast mono-cultures. Quantitative evaluation of the phospho-c-Met and HGF levels by 
chemiluminiscent imaging are shown in the right panel. C Distribution of beta-catenin protein 
(red) in LS174T cells grown in spheroids for 5 days either alone (LS) or as LS174T-CAF co-
cultures (LS+CAF). The percentage of nuclear beta-catenin positive cells was determined 
using quantitative image analysis (scattergrams). Cell nuclei were staine with DAPI (blue). 
The numbers of cells analyzed (n) are indicated. 
Figure 5 
Invasion into the ECM. A Spheroids were made from LS174T cells expressing dsRed and 
cultivated in collagen gels for 11 days in the absence (LS174T-dsR) or presence of cancer 
associated fibroblasts (LS174T-dsR+CAF1). Photomicrographs depict an overlay of dsRed 




invaded into the collagen gel as single cells (white arrows) and cell clusters (black arrows), 
whereas without fibroblasts the tumor spheroids remained with a perfectly distinct border and 
showed no sign of invasion (scale bars: 100 m). B Confocal imaging revealed collective 
invasion of LS174T (CK18 positive, red) into collagen gel areas with high fibroblast density 
(PDGFRß positive, green). Control cultures without fibroblasts did not invade (left panel). 
Nuclei were stained with DAPI (blue), (scale bars: 50 m).  
Figure 6 
Profiling experiments and pathway analysis. A 96 tumor cell spheroids (of defined cell 
numbers) and 2x105 fibroblasts were cultured for 3.5 days in collagen gels either as co-
cultures or as individual cultures. The whole lysates from LS174T mono-cultures were mixed 
with fibroblast mono-culture lysates (mix), thereby ensuring the same amount of tumor and 
fibroblast components present as in the co-culture experiments. Skin fibroblasts (BJ-1, SF), 
normal embryonic colon fibroblasts (CCD18-Co, NCF) and colon cancer associated 
fibroblasts (12051CAF, 13388CAF; CAF1 and CAF2 respectively) were used. All 
experiments were done in biological triplicates. RNA extracted from the mixed as well as 
from the co-culture experiments was processed for Affymetrix GeneChip analysis (see also 
Supplementary Figure 11). A Sammon’s blot is shown. B From GSEA the core genes of 
statistically significant gene-sets were used to calculate PCA plots. A clear-cut segregation of 
the co-culture and the mixed-mono-culture experiments can be made (dotted line). Activation 
of ras-oncogenic-signalling detected in the c2 curated gene sets is shown. C A 35 gene 
network clustering around NF-kappa B revealed by Pathway analysis (Ingenuity®). In this 
network regulation (up: red, down: green) by distinct fibroblast origins is indicated. Dashed 
blue circles indicate gene expression changed by the presence of colon fibroblasts; genes 
altered by CAFs are boxed by dashed orange squares. Genes regulated by the presence of any 
fibroblast type are not encircled.  
Figure 7 
Selected genes induced by the co-cultivation of LS175T cells with stromal fibroblasts. A Left: 
Whisker-box plots displaying the expression profile of CEACAM5 (yellow: mixed individual 
cultures, blue: co-cultures). Right: Confocal images and quantification of CEA 
immunofluorescence staining (green) of LS174T spheroids alone and LS174T spheroids co-
cultured with 13388CAFs (CAF2). Nuclei are counterstained with DAPI (blue). 




protein expression upon co-culture. Error bars are S.D. from four different spheroids. B The 
expression profile of CXCL8 (IL-8, left) was validated by determining CXCL8 levels in 
conditioned medium of mono- and co-cultures (right). Error bars: S.D. of three measurements. 
C DMBT1 expression was selectively induced by the co-culture with CAFs (left). DMBT1 
displayed a unique expression pattern in normal tissues versus major tumor types as 
determined by the GeneExpress database (GeneLogic). The bold centre-line indicates the 
median; the box represents the interquartile range (IQR). Whiskers extend to 1.5 times the 
IQR. Outliers are depicted as black circles. 
 
Figure 8 
Reduced tumor growth by inhibition of the PI3K pathway. A LS174T spheroids were cultured 
individually or together with fibroblasts in collagen gels and photographed daily. The top 
panel shows photomicrographs of a time-lapse experiment. B The increase in the mean 
volume of six spheroids is shown graphically (error bars: S.D.) and can be defined to be equal 
to tumor growth. C LS174T spheroids were cultured in fibroblast containing collagen gels for 
three days and subsequently treated with 5µM of the PI3K inhibitor LY294002 for another 
four days. Untreated control cultures are shown for comparison. The bars indicate the mean 
volume of eight individual spheroids followed for four days under each condition. Error bars 
are S.D. Treated versus untreated cultures at day 7 are depicted in micrographs above the 
diagram. D Sections of LY294002 treated and untreated cultures from (a) were stained with 
anti-cleaved-caspase 3. The percentage of positive tumor cells and fibroblasts were 
determined based on total cell number (present nuclei) and were graphically displayed (total 
number of nuclei: n=494 in control cultures, n=335 in LY294002 treated gels, error bars are 
S.D. of 10 microscopic fields). E Sections as in D were stained with anti phospho-Histone H3. 
The mitotic indices were determined by counting phospho-H3 positive tumor cells from 
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Genes upregulated by hypoxia 
in normal fibroblasts from 
young and old donors 
Kim et al., Mech Ageing 
Dev. 2003 Aug-
Sep;124(8-9):941-9. 
LEE_CIP_UP 60 0,004 
Genes upregulated in 
hepatoma induced by 
ciprofibrate 
Lee et al., Nat Genet. 
2004 
Dec;36(12):1306-11. 
IRS_KO_ADIP_UP 28 0,006 
Genes up-regulated in 
preadipocytes with  defects 
in adipocyte differentiation 
(Irs4 KO, Irs2 KO, Irs3 KO, 
Irs1 KO) 
Tseng et al., Nat Cell 
Biol. 2005 
Jun;7(6):601-11. 
           
Table 1 
List of the most significantly enriched pathways sorted by the Normalized Enrichment Score 
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Publications: 
Original articles: 
 
1: Rupp C, Dolznig H, Haslinger C, Schweifer N, Artaker M, Garin‐Chesa P. 
IGFBP7, a novel tumor stroma marker with dual roles in epithelial‐ and mesenchymal‐type 
tumor cells 
Manuscript prepared for submission to“Cancer Research”. 
 
PhD Thesis  Characterization of novel tumor stroma markers  Mag. Christian Rupp 
154 
 
2:Dolznig H, Rupp C,Puri C,Haslinger C,Schweifer N, Wieser E, Kerjaschki D, Garin‐Chesa P 
Modeling adenocarcinomas in vitro: A novel 3D co‐culture system induces cancer relevant 
pathways upon tumor stroma interaction 
Manuscript prepared for submission to “American Journal of Pathology” 
 
3: Rupp C, Dolznig H, Puri C, Sommergruber W, Kerjaschki D, Rettig WJ, Garin‐Chesa P 
Mouse endosialin, a C‐type lectin‐like cell surface receptor: expression during embryonic 
development and induction in experimental cancer  neoangiogenesis. 
Cancer Immun. 2006 Jul 31;6:10. 
4: Rupp C, Dolznig H, Puri C, Schweifer N, Sommergruber W, Kraut N, Rettig WJ,Kerjaschki D,  
Garin‐Chesa P 
Laser capture microdissection of epithelial cancers guided by antibodies against fibroblast 
activation protein and endosialin. 
Diagn Mol Pathol. 2006 Mar;15(1):35‐42. 
5: Zierhut C, Berlinger M, Rupp C, Shinohara A, Klein F 
Mnd1 is required for meiotic interhomolog repair. 
Curr Biol. 2004 May 4;14(9):752‐62 
6:Rabitsch KP, Tóth A, Gálová M, Schleiffer A, Schaffner G, Aigner E, Rupp C, Penkner AM, 
Moreno‐Borchart AC, Primig M, Esposito RE, Klein F, Knop M, Nasmyth K. 
A screen for genes required for meiosis and spore formation based on whole‐genome 
expression. 
Curr Biol. 2001 Jul 10;11(13):1001‐9. 
Review: 
 
Rupp C, Dolznig H, Haslinger C, Schweifer N, Garin‐Chesa P 
Cancer associated fibroblasts as therapeutic targets 
Accepted for publication in: 
“Tumor associated fibroblasts and their matrix” published by Springer, edited by N. Fusenig 
& M. Mueller (DKFZ, Heidelberg) 
 
Several poster presentations 
 
Languages & Computer Skills 
 
Languages:          German (native); English (fluent); French (good knowledge); Italian (basics) 
 
Computer skills: Microsoft Office; Graphic programs (Adobe Photoshop, Macromedia 
Freehand); Biological     databases (EMBL, Swissprot, Medline…); Expression profiling 
(GeneLogic Bioexpress)  
 
 
 
 
